Document:

exv10w12

EXHIBIT 10.12

ROYALTY AND LICENSE AGREEMENT

     This License Agreement (this “AGREEMENT”) is entered into and effective upon the date of last
signature herein (the “EFFECTIVE DATE”), by and between Integral LifeSciences Corporation, a
corporation organized under the laws of the State of Delaware, having a business office at 105
Morgan Lane, Plainsboro, New Jersey 08536 (hereinafter referred to as “INTEGRA”), and REVA Medical,
Inc., a corporation duly organized and existing under the laws of California, having its principal
office at 5751 Copley Drive, Suite B, San Diego, CA 92111 (hereinafter referred to as “REVA”).

WITNESSETH

     WHEREAS, concurrently with this AGREEMENT, INTEGRA and Rutgers, The State University of New
Jersey, having its statewide Office of Corporate Liaison and Technology Transfer at ASB Annex III,
3 Rutgers Plaza, New Brunswick, New Jersey 08901-8559 (“RUTGERS”) shall execute a certain License
Termination Agreement (“LICENSE TERMINATION AGREEMENT”), an executed copy of which is attached
hereto as Appendix A, terminating the Exclusive License Agreement between INTEGRA and RUTGERS dated
January 13, 1995. Pursuant to the LICENSE TERMINATION AGREEMENT certain inventions, technology,
and intellectual property thereunder, revert or are assigned to RUTGERS.

     WHEREAS, REVA desires that INTEGRA enter into the LICENSE TERMINATION AGREEMENT; and

     WHEREAS, INTEGRA has made certain inventions with regard to the manufacturing and production
of certain polycarbonates as more specifically set forth in Appendix B (to the extent that such
inventions have not reverted or been assigned to RUTGERS pursuant to the LICENSE TERMINATION
AGREEMENT, the “INTEGRA TECHNOLOGY”);

     WHEREAS, INTEGRA is the owner of certain “INTELLECTUAL PROPERTY” (as defined herein below)
arising out of or under the INTEGRA TECHNOLOGY and has the right to grant licenses under and to
such INTELLECTUAL PROPERTY;

     WHEREAS, REVA desire to license rights from INTEGRA with regard to the INTEGRA TECHNOLOGY and
the INTELLECTUAL PROPERTY thereunder, for certain royalty payments set forth herein;

     NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein and for
good and valuable consideration, the adequacy and sufficiency of which is hereby acknowledged, the
parties hereby agree as follows:

ARTICLE I — DEFINITIONS

     All definitions below or elsewhere in this AGREEMENT apply to both their singular and plural
forms, as the context may require. “H/herein,” “hereunder,” and “hereof” and other similar
expressions refer to this AGREEMENT. “Article(s)” and “Section(s)” refer to a

 

 

section(s) in this AGREEMENT. “I/including” means “including without limitation.” “D/day(s)”
means “calendar day(s),” unless otherwise stated.

     1.1 “CONFIDENTIAL INFORMATION” means the proprietary or confidential information of a party
(each, a “DISCLOSER”) which is disclosed to the other party (each, a “RECIPIENT”) before or after
the EFFECTIVE DATE and (i) is identified as “confidential” by DISCLOSER in writing prior to
disclosure and (ii) relates to products, plans, designs, costs, prices, finances, marketing plans,
business opportunities, personnel, research, development, know-how, trade secrets, inventions,
blueprints, techniques, chemical or biological materials, drugs, devices, specimens, apparatus,
processes, algorithms, software programs, schematics, designs, contracts, customer lists,
procedures, formulae, patent applications and other information relating to DISCLOSER’s business,
services, processes or technology. CONFIDENTIAL INFORMATION shall not include information that:
(i) was known by RECIPIENT, or was publicly available, prior to disclosure by DISCLOSER to
RECIPIENT; (ii) become publicly available after disclosure by DISCLOSER to RECIPIENT through no act
of RECIPIENT; (iii) is hereafter rightfully furnished to RECIPIENT by a third party without
confidentiality restriction; or (iv) is disclosed with the prior written consent of DISCLOSER or as
expressly authorized under this AGREEMENT.

     1.2 “FIELD” shall mean the field of or related to products for blood vessels.

     1.3 “FIRST GENERATION MATERIAL” shall mean the family of desaminotyrosyl-L-tyrosine derived
polycarbonates which include poly(DTE-carbonate), poly(DTB-carbonate), poly(DTH-carbonate),
poly(DTO-carbonate) and poly(X%DTR-co-Y%DT-carbonate)s and tyrosine derived polycarbonates
containing the chain-terminating groups derived from acetic anhydride or the ethyl, butyl, hexyl,
or octyl esters of L-tyrosine or desamino tyrosine. FIRST GENERATION MATERIAL are further
described in subsections (a) and (d) of the definition of “POLYCARBONATES,” as set forth in
Appendix C.

     1.4 “INTELLECTUAL PROPERTY” means the PATENT RIGHTS and the TECHNICAL INFORMATION AND RIGHTS.

     1.5 “LICENSED PRODUCT” shall mean (i) any product or part thereof in the FIELD which is
covered in whole or claimed in at least one unexpired claim of PATENT RIGHTS or RUTGERS PATENT
RIGHTS in the country in which any such product or part thereof is made, used, or sold by LICENSEE
or its sublicensees; and (ii) any product made by any process which is covered in whole or claimed
in at least one unexpired claim of PATENT RIGHTS or RUTGERS PATENT RIGHTS in the country in which
any such process is used to make such product or part thereof by REVA.

     1.6 “PATENT RIGHTS” shall mean all of the following patent applications and patents, but only
to the extent that such have not reverted or been assigned to RUTGERS pursuant to the LICENSE
TERMINATION AGREEMENT, including, without limitation:

          (a) US Pat # 6,359,102, issued on March 19, 2002, entitled, “Biphasic polymerization process,”
EP0991693A1, issued on April 12, 2000, entitled, “Biphasic

2

 

polymerization process,” EP0991693B1, issued on September 3, 2003, entitled, “Biphasic
polymerization process,” and US Pat # 6620356, issued on September 16, 2003, entitled, “Porous
constructs fabricated by gas induced phase inversion,” together with all pending and issued foreign
counterparts of such application; and all pending and issued renewals, continuations,
continuations-in-part, divisions, patents of addition, reexaminations and/or reissues of such
application or foreign counterparts;

          (b) United States Patent Application 10/350,202 and any other pending, issued or hereafter
filed, U.S. or foreign patents applications owned by INTEGRA covering the INTEGRA TECHNOLOGY; and

          (c) Any United States or foreign patent application or patent that claims a right of priority
from any of the patents or patent applications in Section 1.6 (a) or (b).

     1.7 “RUTGERS PATENT RIGHTS” shall: (i) have the meaning set forth in the LICENSE TERMINATION
AGREEMENT for the term “Rutgers’ Patent Rights” and shall also include any additional patents,
patent applications, all pending and issued foreign counterparts of such applications; and all
pending and issued renewals, continuations, continuations-in-part, divisions, patent of addition,
reexaminations and/or reissues of such applications or foreign counterparts, to which rights have
reverted from, or been assigned by, INTEGRA to RUTGERS pursuant to the LICENSE TERMINATION
AGREEMENT; and (ii) include the U.S. Patent Application Numbers and provisional patents listed on
Appendix C and patents issuing thereon, the U.S. Patent Number(s) listed on Appendix C, and shall
also include any additional patents, patent applications, all pending and issued foreign
counterparts of such applications; and all pending and issued renewals, continuations,
continuations-in-part, divisions, patent of addition, reexaminations and/or reissues of such
applications or foreign counterparts.

     1.8 “SECOND GENERATION MATERIAL” shall mean FIRST GENERATION MATERIAL that are radiopaque
(using iodine and/or bromine) and/or PEGylated and are further described in subsections (a) and (d)
of the definition of “POLYCARBONATES,” as set forth in Appendix C.

     1.9 “TECHNICAL INFORMATION AND RIGHTS” shall mean copyrights, moral rights, data rights,
business processes, trade secrets, all technical information, know-how, formulations,
specifications, processes, techniques and data, and any other proprietary right arising or
enforceable under the laws of the United States, any other country, or any bilateral or
multilateral treaty that arises from a laboratory of INTEGRA or exists at the time of this
AGREEMENT which are not readily available to others through public means, (i) other than the PATENT
RIGHTS, and (ii) only to the extent that such information and/or rights have not reverted or been
assigned to RUTGERS pursuant to the LICENSE TERMINATION AGREEMENT.

     1.10 “TERRITORY” shall mean the entire world.

ARTICLE II  — THE LICENSE

     2.1 Subject to the terms and conditions of this AGREEMENT, INTEGRA hereby grants to REVA and
REVA hereby accepts from INTEGRA an exclusive right in the

3

 

TERRITORY in the FIELD, with right to sublicense as set forth in Section 2.2, (a) to the
INTELLECTUAL PROPERTY and (b) to make, have made, modify, distribute, lease, import, use, offer to
sell, have sold and otherwise dispose of LICENSED PRODUCTS and (c) to use, have used, perform and
have performed processes under the INTELLECTUAL PROPERTY.

     2.2 REVA shall have the exclusive right, at its sole discretion, to sublicense any of the
rights, privileges and licenses granted hereunder during the term of this AGREEMENT.

     2.3 All sublicenses granted by REVA of its rights hereunder shall be subject to terms
substantially similar to this AGREEMENT and if a sublicense allows sublicensee to sell the LICENSED
PRODUCTS, such sublicense shall provide for the payment of running royalties for the sale of such
LICENSED PRODUCTS hereunder at amounts equal to the amount specified for payments by REVA to
INTEGRA in Section 5.2 hereof. REVA agrees to forward to INTEGRA a copy of reports received by
REVA from its sublicensees under the sublicenses as shall be pertinent to a royalty accounting
regarding the sale of LICENSED PRODUCTS, if any, under sublicense agreements.

     2.4 The parties recognize and acknowledge that REVA’s reasonable efforts to develop and market
the LICENSED PRODUCTS may not result in the commercialization of the LICENSED PRODUCTS or profits
from such commercialization.

ARTICLE III - LICENSE RESTRICTIONS AND ENFORCEMENT

     3.1 No license or other right is granted, by either party to the other, by implication,
estoppel or otherwise, under any intellectual property now or hereafter owned or controlled by such
party except for the licenses and rights expressly granted in this AGREEMENT.

     3.2 At any time or from time to time on and after the EFFECTIVE DATE, each party shall, at the
request of the other party, (i) deliver to the requesting party such records, data or other
documents consistent with this AGREEMENT; (ii) execute, and deliver or cause to be delivered, all
such assignments or further instruments of transfer or license, and (iii) take or cause to be taken
all such other actions, as the requesting party may reasonably deem necessary or desirable in order
for the requesting party to obtain the full benefits of this AGREEMENT and the transactions
contemplated hereby.

ARTICLE IV - OWNERSHIP

     4.1 REVA shall retain all rights, title and interests in and to of all REVA’s intellectual
property, and any and all other tangible forms thereof.

     4.2 Except for the license grants set forth in Article II, INTEGRA shall retain all rights,
title and interests in and to all of INTEGRA’S INTELLECTUAL PROPERTY.

ARTICLE V - PAYMENTS

     5.1 In consideration of the license grants and for executing the LICENSE TERMINATION
AGREEMENT, among other good and valuable consideration, REVA shall

4

 

pay INTEGRA a royalty of: (i) *** U.S. Dollars ($***) per unit in the
United States and Japanese markets, and *** U.S. Dollars ($***) per unit in all other
territories, only on coronary stents made from FIRST GENERATION MATERIALS sold by REVA or a
sublicensee of REVA, as appropriate (but in no instances both REVA and sublicensee of REVA so to
create a “double royalty” for INTEGRA); and (ii) *** U.S. Dollars and *** Cents ($***) per unit
only on coronary stents made from SECOND GENERATION MATERIALS sold by REVA or a sublicensee of
REVA, as appropriate (but in no instances both REVA and sublicensee of REVA so to create a “double
royalty” for INTEGRA). Such royalties shall be payable as provided in Section 5.3.

     5.2 Payment of the royalties specified in Section 5.1, if any such royalty is due, for the
preceding calendar quarter shall be made by REVA to INTEGRA within thirty (30) days after March 31,
June 30, September 30 and December 31 of each year during the term of this AGREEMENT. After
termination or expiration of this AGREEMENT, a final payment shall be made by REVA covering the
last whole or partial calendar quarter. Each quarterly payment shall be accompanied by a written
statement of royalties due, as described in Section 6.2 hereunder.

     5.3 All monetary payments due hereunder are expressed in and shall be paid by check payable in
United States dollars, without deduction of exchange, collection or other charges, to INTEGRA.

     5.4 For converting into United States dollars any monetary payment accrued hereunder in the
currency of any other country, the rate of exchange for the purchase of United States dollars with
such currency quoted by The Chase Manhattan Bank, New York, New York, on the last business day of
the payment period in question shall be used.

     5.5 No multiple royalties shall be payable because any LICENSED PRODUCTS, their manufacture,
use, lease or sale are or shall be covered by more than one patent application, patent or
certificate of registration licensed under this AGREEMENT. For avoidance of doubt, REVA has no
obligations under this AGREEMENT to make any royalty, milestone or maintenance payments to INTEGRA,
except as explicitly set forth in Section 5.1.

ARTICLE VI - REPORTS AND RECORDS

     6.1 REVA shall keep and preserve, in accordance with generally accepted accounting principles
and procedures, complete and accurate books, records and accounts containing particulars that are
necessary for the purpose of showing the amounts payable to INTEGRA hereunder. Said books, records
and accounts shall be kept at REVA’s principle place of business or the principle place of business
of the appropriate division of REVA to which this AGREEMENT relates. No more than once per annum
said books and supporting data shall be open, upon reasonable notice at all reasonable times and
places during business hours for two (2) years following the end of the calendar year to which they
pertain, to the inspection of an independent auditor engaged at INTEGRA’S cost (that has signed a
confidentiality agreement at least as protective of REVA’s CONFIDENTIAL INFORMATION as Article XII)
mutually

 

			
	***	 	Portions of this page have been omitted
pursuant to a request for Confidential Treatment filed separately with the
Commission.

5

 

agreeable to the parties for the purpose of verifying REVA’s royalty statement or compliance
in other respects with this AGREEMENT.

     6.2 REVA shall, within thirty (30) days after March, 31, June 30, September 30 and December
31, of each year, deliver to INTEGRA true and accurate reports, giving such particulars of the
business conducted by REVA and its sublicensees during the preceding calendar quarter under this
AGREEMENT as shall be pertinent to a royalty accounting hereunder. These reports shall be duly
signed by an authorized signatory of REVA on behalf of REVA and shall include at least the
following:

          (a) number of LICENSED PRODUCTS which are coronary stents made from FIRST GENERATION MATERIALS
and the number of LICENSED PRODUCTS which are coronary stents made from SECOND GENERATION MATERIALS
manufactured and sold by REVA and its sublicensees;

          (b) total royalties due; and

          (c) names and addresses of all sublicensees of REVA.

     6.3 With each such report submitted, REVA shall pay to INTEGRA the royalties due and payable
under this AGREEMENT. If no royalties are due, REVA shall so report.

     6.4 REVA shall use the royalty reporting sheet attached hereto as Appendix D, or a substantial
equivalent, to fulfill the royalty and reporting requirements of this Article VI.

ARTICLE VII - PATENT PROSECUTION AND MAINTENANCE

     7.1 Responsibility for Patent Prosecution. Within thirty (30) days after the
EFFECTIVE DATE, INTEGRA shall deliver to REVA all relevant United States or foreign filings for any
PATENT RIGHTS which were filed on any date prior to thirty (30) days after the EFFECTIVE DATE.
Subject to this Article VII, REVA shall file, prosecute, and maintain the PATENT RIGHTS during the
term of this AGREEMENT. REVA shall keep INTEGRA advised of the continuing prosecution of the
PATENT RIGHTS. REVA shall provide INTEGRA with a copy of each relevant proposed United States and
foreign filing for the PATENT RIGHTS at least fifteen (15) days prior to the date of such filing so
that INTEGRA may be informed of the continuing prosecution and have an opportunity to review and
comment on such filings and upon the breadth and scope of the related patent applications of the
PATENT RIGHTS.

     7.2 Payments for Patent Filings. Payment of all fees and costs relating to the
filing, prosecution, maintenance and defense of PATENT RIGHTS shall be borne by REVA. In the event
INTEGRA has entered, or enters, into licenses with third parties outside the FIELD, INTEGRA shall
require said parties to pay a pro-rata share of said prior expenses to REVA.

     7.3 Abandonment by REVA. If REVA decides not to continue payment for prosecution of a
United States or foreign patent application to issuance or grant, or decides not to continue
payment for maintenance of any United States or foreign patent application or patent within the
PATENT RIGHTS, then (a) REVA shall timely notify INTEGRA in writing in order that INTEGRA may
continue said prosecution or maintenance of such intellectual property at

6

 

INTEGRA’S own expense, and (b) from and after the date of the written notice under (a), REVA
shall have no further obligation to pay any fees or costs relating to the filing, prosecution, or
maintenance of such patent application or patent of the PATENT RIGHTS, and REVA’s license with
regard to such patent application or patent shall cease become non-exclusive (but only for the
applicable country or countries in which REVA has decided not to continue prosecution or not to
maintain such patent application or patent of the PATENT RIGHTS).

ARTICLE VIII - INFRINGEMENT AND OTHER ACTIONS

     8.1 Notice. Each of the parties, as a notifying party, shall promptly provide to the
other party (a) written notice of any alleged infringement by a third party of any patent licensed
hereunder under PATENT RIGHTS, and (b) any available evidence of any infringement referenced in (a)
that is in such notifying party’s possession or control.

     8.2 Infringement. REVA, at its expense, may enforce the PATENT RIGHTS licensed
hereunder against infringement by third parties and is entitled to retain recovery from such
enforcement. INTEGRA hereby agrees that REVA may join INTEGRA as a party in any such action (with
INTEGRA having the right to participate in such action and to be represented, if it so desires and
at its own expense, by counsel of its own selection) and to give REVA reasonable assistance and any
needed authority to control, file and prosecute such action, without expense to INTEGRA. REVA
agrees to keep INTEGRA reasonably informed as to the status of any such action and to provide
copies to INTEGRA, upon request by INTEGRA, of any papers or information relevant to the
prosecution of any such action. REVA shall timely inform INTEGRA of any offer for settlement
presented by a third party for any such action and REVA shall consider INTEGRA’S input in deciding
whether or not to accept any such settlement offer. The total cost of any such action, commenced
or defended solely by REVA, shall be borne by REVA. After reimbursement of REVA’s reasonable legal
costs and expenses related to such recovery, REVA agrees to pay INTEGRA the royalty detailed in
Section 5.1 for any monetary recovery that is for sales of coronary stents which are LICENSED
PRODUCTS lost due to the infringement and a pro-rata portion of any related punitive or
consequential damages awarded REVA.

     8.3 Right to Withhold. If REVA undertakes to prosecute and/or defend any action
alleging infringement of, and/or any action challenging the validity of, any of the PATENT RIGHTS,
as provided in Section 8.2, REVA may withhold up to fifty percent (50%) of the payments otherwise
thereafter due INTEGRA under Article V hereunder and apply the same toward reimbursement of up to
one-half (1/2) of REVA’s expenses, including attorneys’ fees, in connection therewith.

     8.4 Cooperation. In any action brought by REVA under this Article VIII, INTEGRA
shall, at the request and expense of REVA, cooperate in all respects and, to the extent possible,
have its employees testify when requested and make available relevant records, papers, information,
samples and specimens.

     8.5 Licenses to Abate Third Party Infringement. REVA shall have the sole right in
accordance with the terms and conditions herein to sublicense any alleged infringer for the

7

 

FIELD to the INTELLECTUAL PROPERTY of no greater scope than set forth in Section 2.1. Any
royalties as part of such a sublicense shall be treated per Article V.

     8.6 Licenses to Abate Own Infringement. If a third party asserts that a patent or
other right owned by it is infringed by the manufacture, import, use, sale or offer for sale of any
LICENSED PRODUCT, the party first obtaining knowledge of such a claim shall immediately provide the
other party notice of such claim and the related facts in reasonable detail. Notwithstanding any
provision in this AGREEMENT to the contrary, except subject to the indemnification provisions of
Article XI, the defense of any such claim (including without limitation the institution and
prosecution of any counterclaims thereto) shall be controlled by REVA, and REVA shall have the
right to enter into settlements, stipulated judgments or other voluntary, final disposition
respecting such claim (and related counterclaims). If REVA should be of the reasonable opinion
that it cannot commercially reasonably make, use, sell, offer for sale, or import any of the
LICENSED PRODUCTS because the INTELLECTUAL PROPERTY or RUTGERS PATENT RIGHTS (or such other
intellectual property right licensed by REVA from RUTGERS) infringe a third party patent or other
intellectual property right, REVA shall obtain the consent from INTEGRA, which shall not be
unreasonably withheld, conditioned or delayed, if such party is willing to grant such license, to
credit fifty percent (50%) of any payment payable to the above-mentioned third party for such a
license against the amounts payable to INTEGRA hereunder on a going-forward basis, but in no event
will INTEGRA’S total payments received hereunder each calendar year be reduced by more than fifty
percent (50%). INTEGRA’S consent hereunder shall only be withheld on the basis of a bona fide
independent legal opinion that no such infringement exists. INTEGRA shall be required to provide
or withhold its consent within twenty (20) days of the date of such notice. No response from
INTEGRA within twenty (20) days shall be deemed to be consent.

 ARTICLE IX — REPRESENTATIONS AND WARRANTIES

     9.1 INTEGRA hereby represents and warrants as follows:

          (a) INTEGRA has full power and authority to enter into and perform this AGREEMENT;

          (b) Neither INTEGRA’S entering nor performing this AGREEMENT will violate any contractual
right of or breach any contractual obligation to any third party under any agreement or arrangement
between INTEGRA and such third party;

          (c) INTEGRA has received and currently holds valid and effective assignments of all inventors’
rights in and to the INTEGRA TECHNOLOGY and the INTELLECTUAL PROPERTY, and no other person may
claim rights to the INTEGRA TECHNOLOGY or the INTELLECTUAL PROPERTY;

          (d) There are no outstanding liens, encumbrances, third party rights, agreements or
understandings of any kind, either written, oral or implied, other than the LICENSE. TERMINATION
AGREEMENT, regarding the INTEGRA TECHNOLOGY or the INTELLECTUAL PROPERTY which are inconsistent or
in conflict with any provision of this AGREEMENT;

8

 

          (e) INTEGRA is the owner of, and has not, other than as set forth in the LICENSE TERMINATION
AGREEMENT, assigned any of its rights, title or interests in or to, and is not aware that any other
person or entity has assigned or licensed, or agreed to grant an assignment or license to any third
party any rights, title or interests in or to, the INTEGRA TECHNOLOGY or the INTELLECTUAL PROPERTY;

          (f) INTEGRA shall not assert against REVA and its sublicensees any of INTEGRA’S rights under
any intellectual property of any kind owned or licensed by INTEGRA for any activities by REVA or
its sublicensees related to the discovery, research, development, manufacture or commercialization
of LICENSED PRODUCTS or of any other products sold by REVA or its sublicensees in the FIELD;

          (g) INTEGRA has not received any notice of any potential or threatened claim of infringement
of third party patents and, (i) INTEGRA, is not aware of any facts which could give rise to any
claim of infringement of third party intellectual property relating to the use and practice of the
INTELLECTUAL PROPERTY or the INTEGRA TECHNOLOGY; and (ii) INTEGRA is not aware of any issued or
granted patent that would be infringed by the practice of the INTELLECTUAL PROPERTY as permitted
under the license rights granted in this AGREEMENT;

          (h) There are no court orders, judgments or decrees that impair or restrict the use, validity
or enforceability of the INTELLECTUAL PROPERTY and no action, suit, inquiry, proceeding or
investigation is currently pending before any court, administrative agency or other governmental
body in which such use, validity or enforceability is being challenged or questioned in any way,
either directly or indirectly, by way of claim, counterclaim or affirmative defense, it being
clearly acknowledged by REVA that such representation and warranty does not apply to any
proceedings before any patent office with respect to the prosecution and issuance of any patent;

          (i) To INTEGRA’S knowledge there is no actual infringement by any third party in the FIELD of
the licensed INTELLECTUAL PROPERTY; and

          (j) To INTEGRA’S knowledge, there are no publications, public uses or public sales or offers
for sale to any party other than REVA which would render any of the PATENT RIGHTS invalid.

     9.2 REVA hereby represents and warrants as follows:

          (a) REVA has full power and authority to enter into and perform this AGREEMENT; and

          (b) Neither REVA’s entering nor performing this AGREEMENT will violate any contractual right
of or breach any contractual obligation to any third party under any agreement or arrangement
between REVA and such third party.

     9.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, INTEGRA AND REVA AND THEIR
TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO

9

 

WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAMS, ISSUED OR
PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.

ARTICLE X - LIMITATION OF LIABILITY

     10.1 EXCEPT FOR EACH PARTY’S INDEMNIFICATION OBLIGATIONS WITH REGARD TO INTELLECTUAL PROPERTY
INFRINGEMENT SET FORTH IN ARTICLE XI, OR A BREACH OF ARTICLE XII, CONFIDENTIAL INFORMATION, OR
ARTICLE XVIII, TERMINATION, TO THE MAXIMUM EXTENT PERMITTED BY LAW,

          (a) NEITHER PARTY WILL BE LIABLE FOR ANY DAMAGES WITH RESPECT TO ANY CLAIMS ARISING FROM OR
RELATING TO THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT PRODUCT
LIABILITY OR ANY OTHER THEORY OF LIABILITY, FOR LOST PROFIT, OR OTHER SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES OF ANY CHARACTER, INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF
GOODWILL, WORK STOPPAGE, COMPUTER FAILURE OR MALFUNCTION, LOSS OF DATA, OR OTHER COMMERCIAL DAMAGES
OR LOSSES, EVEN IF THAT PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

          (b) NEITHER PARTY WILL BE LIABLE FOR ANY DAMAGES WITH RESPECT TO ANY CLAIMS ARISING FROM OR
RELATING TO THIS AGREEMENT, WHETHER IN CONTRACT (OTHER THAN FOR PAYMENT OF ROYALTIES), TORT
(INCLUDING NEGLIGENCE), STRICT PRODUCT LIABILITY OR ANY OTHER THEORY OF LIABILITY, THAT EXCEED THE
SUM OF THE AMOUNTS PAID BY REVA TO INTEGRA AND THE AMOUNTS OUTSTANDING OWED BY REVA TO INTEGRA
HEREUNDER PRIOR TO THE DATE OF THE EVENT GIVING RISE TO SUCH LIABILITY. THIS LIMITATION SHALL
APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.

ARTICLE XI - INDEMNIFICATION

     11.1 INTEGRA’S Indemnification. INTEGRA shall at all times during the term of this
AGREEMENT and thereafter, indemnify, defend and hold REVA, its trustees, directors, officers,
employees and affiliates (“REVA’s INDEMNITEES”), harmless against all third party claims,
proceedings, demands and liabilities of any kind whatsoever, including legal expenses and
reasonable attorneys’ fees, arising out of what is judicially determined to be a breach of any
representation or warranty as set forth in Section 9.1, and to pay all damages and costs awarded
against REVA or that arise out of settlement provided that REVA’s INDEMNITEES: (a) promptly notify
INTEGRA in writing of any such suit or proceeding, (b) provides INTEGRA with sole control over the
defense or settlement of such suit or proceeding, and (c) provide reasonable information and
assistance in the defense and/or settlement of any such claim or action. Notwithstanding the
foregoing, INTEGRA’S indemnification obligation with respect to claims arising from or relating to
breaches of representations or warranties that do not relate to INTEGRA’S infringement of a third
party’s intellectual property rights shall (x) exclude

10

 

damages of the type described in Section 10.1(a), and (y) be limited in amount to the sum of
the amounts paid or owed by REVA to INTEGRA hereunder. REVA will have the right to approve any
settlement or compromise that may adversely affect its rights. In the event that REVA disapproves
such settlement and compromise, REVA shall compensate INTEGRA for any additional damages,
liabilities, costs and expenses incurred by INTEGRA resulting from such disapproval.

     11.2 REVA’s Indemnification. REVA shall at all times during the term of this
AGREEMENT and thereafter, indemnify, defend and hold University and INTEGRA, its trustees,
directors, officers, employees and affiliates (“INTEGRA’s INDEMNITEES”), harmless against all third
party claims, proceedings, demands and liabilities of any kind whatsoever, including legal expenses
and reasonable attorneys’ fees, directly arising out of the death of or injury to any person or
persons or out of any damage to property, or directly resulting from the production, manufacture,
sale, use, lease, consumption or advertisement of the LICENSED PRODUCTS by REVA or sublicensees or
arising from any breach of any contractual obligation of REVA hereunder, and to pay all damages and
costs awarded against INTEGRA or that arise out of settlement provided that INTEGRA’S INDEMNITEES:
(a) promptly notify REVA in writing of any such suit or proceeding, (b) provide REVA with sole
control over the defense or settlement of such suit or proceeding, and (c) provide reasonable
information and assistance in the defense and/or settlement of any such claim or action. INTEGRA
will have the right to approve any settlement or compromise that may adversely affect its rights.
In the event that INTEGRA disapproves such settlement and compromise, INTEGRA shall compensate REVA
for any additional damages, liabilities, costs and expenses incurred by REVA resulting from such
disapproval.

ARTICLE XII - CONFIDENTIALITY

     12.1 Nondisclosure. RECIPIENT shall not, except as otherwise expressly provided
herein, disclose, disseminate or otherwise allow access to the CONFIDENTIAL INFORMATION of
DISCLOSER to anyone other than RECIPIENT’S employees that have a need to know such CONFIDENTIAL
INFORMATION to implement this AGREEMENT and who are bound by written confidentiality obligations
with provisions no less stringent than those contained in this ARTICLE XII. RECIPIENT shall
prevent unauthorized disclosure or use of the CONFIDENTIAL INFORMATION of DISCLOSER. DISCLOSER and
RECIPIENT shall execute any documents and otherwise shall take all necessary steps to ensure that
DISCLOSER and RECIPIENT shall each be able to enforce DISCLOSER’s rights hereunder against
RECIPIENT, its employees and all other third parties to whom RECIPIENT discloses DISCLOSER’s
CONFIDENTIAL INFORMATION, under the laws of each jurisdiction in which DISCLOSER’s CONFIDENTIAL
INFORMATION is disclosed by RECIPIENT. RECIPIENT shall be responsible for any breach of this
ARTICLE XII by RECIPIENT’S employees, contractors or agents.

     12.2 Ownership. Except as set forth in ARTICLE TV, RECIPIENT acknowledges and agrees
that DISCLOSER (or its licensors) owns all rights, title and interests, including intellectual
property rights in and to DISCLOSER’s CONFIDENTIAL INFORMATION.

11

 

     12.3 Notification. If RECIPIENT learns or believes that any person who has had access
to the CONFIDENTIAL INFORMATION of DISCLOSER has violated or intends to violate this AGREEMENT,
RECIPIENT shall immediately notify DISCLOSER and shall cooperate with DISCLOSER in seeking
injunctive or other equitable relief against any such person.

     12.4 Exceptions. RECIPIENT may disclose the CONFIDENTIAL INFORMATION of DISCLOSER, if
such disclosure is required by law, provided that RECIPIENT promptly notifies DISCLOSER to allow
intervention by DISCLOSER (prior to the disclosure), cooperates with DISCLOSER to contest or
minimize the disclosure (including application for a protective order) at DISCLOSER’s expense and
limits such disclosure to the party entitled to receive the CONFIDENTIAL INFORMATION and to the
scope of the legal requirement. Notwithstanding the foregoing, any CONFIDENTIAL INFORMATION
disclosed pursuant to this Section 12.4 shall otherwise continue to be treated as CONFIDENTIAL
INFORMATION hereunder.

     12.5 Confidentiality of AGREEMENT. Neither party will publicly disclose any term of
this AGREEMENT or announce the existence of this AGREEMENT without the prior written consent of the
other party, except that each party may reveal the terms of this AGREEMENT (a) to its accountants,
banks, financing sources, lawyers and other professional advisors, provided that such parties
undertake in writing to keep such information confidential, or (b) as required by applicable laws
and regulations including those of the U.S. Securities and Exchange Commission on the notification.
Each party may also disclose the tax treatment and tax structure of the transactions contemplated
by this AGREEMENT and all materials of any kind (including opinions or other tax analyses) that are
provided to it relating to such tax treatment and tax structure.

     12.6 Reproduction of CONFIDENTIAL INFORMATION. CONFIDENTIAL INFORMATION shall not be
reproduced except as reasonably required to implement this AGREEMENT. Any reproduction or
derivative of any CONFIDENTIAL INFORMATION of DISCLOSER by RECIPIENT shall remain the property of
DISCLOSER and shall contain all confidential or proprietary notices or legends which appear on the
original.

ARTICLE XIII - EXPORT CONTROLS

     13.1 It is understood that INTEGRA is subject to United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes and other
commodities (including the Arms Export Control Act, as amended and the Export Administration Act of
1979). The transfer of certain technical data and commodities may require a license from the
cognizant agency of the United States Government and/or written assurances by REVA that REVA shall
not export data or commodities to certain foreign countries without prior approval of such agency.
INTEGRA shall assist REVA to comply with the United States export laws and regulations set forth in
this Section 13.1.

ARTICLE XIV - NON-USE OF NAMES

     14.1 REVA shall not use the names or trademarks of INTEGRA, or any of its employees, or any
adaptation thereof, in any advertising, promotional or sales literature without

12

 

prior written consent obtained from INTEGRA, in each case, except that REVA may, without prior
written consent, state that it is licensed by INTEGRA, under one or more of the patents and/or
applications comprising the PATENT RIGHTS.

ARTICLE XV - PAYMENTS. NOTICES AND OTHER COMMUNICATIONS

     15.1 Any payment, notice or other communication pursuant to this AGREEMENT shall be
sufficiently made or given on the date of mailing if sent to such party by certified or registered
first class mail, postage prepaid, addressed to it at its address below or as it shall designate by
written notice given to the other party as follows:

In the case of INTEGRA:

To the Attention of: General Counsel

Integra LifeSciences Corporation

105 Morgan Lane

Plainsboro, New Jersey 08536

In the case of REVA:

To the Attention of: Robert Schultz, President

REVA Medical, Inc.

5751 Copley Drive, Suite B

San Diego, CA 92111

ARTICLE XVI - ASSIGNMENT

     16.1 Neither this AGREEMENT nor any right or obligation hereunder is assignable in whole or in
part by any party without the prior written consent of the other party. Notwithstanding the
foregoing, either party may assign this AGREEMENT, without such consent to a third party in
connection with any merger, acquisition, consolidation, reorganization (in which a change of
control occurs), CHANGE OF CONTROL of or by the assigning party, or sale of all, substantially all
or a majority of such parties’ assets or voting securities. A “CHANGE OF CONTROL” occurs when over
fifty percent (50%) of a party’s then outstanding securities are acquired by a third party. This
AGREEMENT shall inure to the benefit of each of the party’s successors and assignees provided that
such successors or assignees assume the party’s obligations under this AGREEMENT.

ARTICLE XVII - DISPUTE RESOLUTION

     17.1 This AGREEMENT is entered into in and shall be governed, construed and enforced in all
respects solely and exclusively under the laws of the State of California, USA without giving
effect to any law which would result in the application of a different body of law.

     17.2 Any and all claims, disputes or controversies arising under, out of, or in connection
with this AGREEMENT, including any dispute relating to patent validity or

13

 

infringement, which the parties shall be unable to resolve within sixty (60) days, shall be
mediated in good faith. The party raising such dispute shall promptly advise the other party of
such claim, dispute or controversy in a writing which describes in reasonable detail the nature of
such dispute. By not later than five (5) business days after the recipient has received such
notice of dispute, each party shall have selected for itself a representative who shall have the
authority to bind such party, and shall additionally have advised the other party in writing of the
name and title of such representative. By not later than ten (10) business days after the date of
such notice of dispute, the party against whom the dispute shall be raised shall select a mediation
firm in San Diego, California and such representatives shall schedule a date with such firm for a
mediation hearing. The parties shall enter into good faith mediation and shall share the costs
equally.

     17.3 If the representatives of the parties have not been able to resolve a dispute within
fifteen (15) business days after a mediation hearing, as set forth in Section 17.2, the parties
shall have the right to pursue any other remedies legally available to resolve such dispute solely
and exclusively in, and the parties hereby irrevocably consent to the exclusive jurisdiction and
proper venue of, the state and federal courts located in the County of San Diego, State of
California, USA, and waive any objections thereto based on any ground including improper venue or
Forum Non-Conveniens. The parties agree that service of process may be effected in accordance with
Article XV. Any decision rendered by such court shall be binding, final and conclusive upon the
parties, and a judgment thereon may be entered in, and enforced by, any court having jurisdiction
over the party against which an award is entered or the location of such party’s assets.

     17.4 Notwithstanding anything to the contrary herein, each party shall be entitled to seek
injunctive or other equitable relief, wherever such party deems appropriate in any jurisdiction, in
order to preserve or enforce such party’s rights for any breach or threatened breach of the other
party of Articles II, IV or XII. Each party agrees that: (i) Articles II, IV and XII are
necessary and reasonable to protect the other party and its business, (ii) any violation of these
provisions could cause irreparable injury to the other party for which money damages would be
inadequate, and (iii) as a result, the other party will be entitled to seek and obtain injunctive
relief against the breach or threatened breach of the provisions of Articles II, IV or XII without
the necessity of posting bond or proving actual damages. The parties agree that the remedies set
forth in this Section 17.4 are in addition to and in no way preclude any other remedies or actions
that may be available at law or under this AGREEMENT.

ARTICLE XVIII - TERM AND TERMINATION

     18.1 Unless earlier terminated as hereinafter provided, this AGREEMENT shall continue until
the later of the end of the life of the last to expire patent of the PATENT RIGHTS and the end of
the life of the last to expire patent of the RUTGERS PATENT RIGHTS. The term of the license for
TECHNICAL INFORMATION AND RIGHTS set forth in Section 2.1 shall last until the later of the end of
the life of the last to expire patent of the PATENT RIGHTS, the end of the life of the last to
expire patent of the RUTGERS PATENT RIGHTS and fifteen (15) years from the EFFECTIVE DATE.

     18.2 If REVA shall cease to carry on its business, this AGREEMENT shall terminate upon notice
by INTEGRA.

14

 

     18.3 Upon any default by REVA of its obligation to pay INTEGRA the royalties set forth in
ARTICLE V, INTEGRA shall have the right to terminate this AGREEMENT and the rights, privileges and
license granted hereunder effective on three (3) months notice to REVA. Such termination shall
become automatically effective unless REVA shall have cured any such default prior to the
expiration of the three (3) month period.

     18.4 Upon termination or expiration of this AGREEMENT for any reason, nothing herein shall be
construed to release either party from any obligation that matured prior to the effective date of
such termination; and Articles I, IV, VI, IX — XV, XVII and XIX and Section 18.4 shall survive any
such termination by their terms. REVA and any sublicensee thereof may, however, after the
effective date of such termination, sell all LICENSED PRODUCTS, and complete LICENSED PRODUCTS in
the process of manufacture at the time of such termination and sell the same, provided that REVA
shall make the payments to INTEGRA as required by Article V and shall submit the reports required
by Article VI hereof. Except as necessary to carry out the terms of this Section 18.4, upon
termination each party shall immediately return the other party’s CONFIDENTIAL INFORMATION, and any
copies thereof in any form, or certify the destruction of the same.

ARTICLE XIX - MISCELLANEOUS PROVISIONS

     19.1 Entire Agreement. This AGREEMENT, including Appendices A, B, C and D embodies
the sole, final and entire understanding of the parties and shall supersede all previous
communications, representations, or undertakings, either verbal or written, between the parties
relating to the subject matter hereof.

     19.2 Amendment. This AGREEMENT may be amended only by a written agreement embodying
the full terms of the amendment signed by authorized representatives of both parties.

     19.3 Severability. If one or more provisions in this AGREEMENT are ruled entirely or
partly invalid or unenforceable by any court or governmental authority of competent jurisdiction,
then: (i) the validity and enforceability of all provisions not ruled to be invalid or
unenforceable shall remain unaffected; (ii) the effect of such ruling shall be limited to the body
making the ruling; (iii) the provision(s) held wholly or partly invalid or unenforceable shall be
deemed amended, and the parties shall reform the provision(s) to the minimum extent necessary to
render them valid and enforceable in conformity with the parties’ intent as manifested herein; and
(iv) if the ruling, or the controlling principle of law or equity leading to the ruling, is
subsequently overruled, modified, or amended, then the provision(s) in question, as originally set
forth in this AGREEMENT, shall be deemed valid and enforceable to the maximum extent permitted by
the new controlling principle of law or equity.

     19.4 No Strict Construction. The language used in this AGREEMENT shall be deemed to
be the language chosen by both parties hereto to express their mutual intent and no rule of strict
construction against either party shall apply to any term or condition of this AGREEMENT.

15

 

     19.5 Relationship of Parties. The parties are independent contractors. Nothing
contained in this AGREEMENT shall be construed as creating a partnership, joint venture, agency or
an association of any kind.

     19.6 No Waiver. The failure of one party hereto to enforce at any time any of the
provisions of this AGREEMENT, or any rights in respect thereto, or to exercise any election herein
provided, shall in no way be considered to be a waiver of such provision, rights or elections or in
any way to affect the validity of this AGREEMENT, or excuse a similar subsequent failure to perform
any such term or condition by the other party. Any waiver must be in writing.

     19.7 Interpretation. The headings of sections contained herein are inserted for
convenience of reference only, and are not intended to be a part of or to affect the meaning or
interpretation of this AGREEMENT.

     19.8 Counterparts. This AGREEMENT may be executed in two counterparts, each of which
will be deemed an original, but together will constitute one and the same instrument. A party may
deliver this AGREEMENT by transmitting a facsimile of this AGREEMENT signed by such party to the
other party, which facsimile signature shall be deemed an original for all purposes.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

16

 

     IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each caused
a duly authorized representative to execute this AGREEMENT on the day and year set forth below.

	 	 	 	 	 
	REVA MEDICAL, INC.

(REVA)

 	 
	By:  	/s/ Robert K. Schultz
 	 
	 	Name:Robert K. Schultz
 	 
	 	Title: President
 	 
	 	Date: 1/30/04
 	 

	 	 	 	 	 
	INTEGRA LIFESCIENCES CORPORATION

(INTEGRA)

 	 
	By:  	/s/ Stuart Essig
 	 
	 	Name:Stuart
Essig	 
	 	Title: CEO	 
	 	Date: 1/25/04	 

17

 

Appendix A

LICENSE TERMINATION AGREEMENT

Appendix A - 1

 

AGREEMENT

     This
Agreement (the “Agreement”) is made as of the 27 day of
January, 2004, by and
between Rutgers, The State University of New Jersey, having its statewide administrative offices at
New Brunswick, New Jersey (hereafter referred to as “Rutgers”), and Integra LifeSciences
Corporation, a corporation organized under the laws of the State of Delaware, having a business
office at 311 Enterprise Drive, Plainsboro, New Jersey 08536 (hereinafter referred to as
“Integra”).

Recitals

     WHEREAS, Rutgers and Integra are parties to an Exclusive License Agreement made effective as
of the 31st day of December, 1994, and amended from time to time thereafter (the Exclusive License
Agreement and amendments hereinafter referred to collectively as the “License Agreement”); and

     WHEREAS, Rutgers and Integra wish to terminate the License Agreement and enter a new and
different contractual relationship;

     NOW, THEREFORE, the parties agree as follows:

     1. Definitions.

          1.1 The defined terms in the License Agreement shall have the same meanings when they are used
in this Agreement.

          1.2 “First Generation Polycarbonates” shall mean Licensed Products in the “Licensed Field,” as
those terms are defined in the License Agreement, covered by the patents or patent applications
identified in Schedule B attached hereto. First Generation Polycarbonates shall not include Second
Generation Polycarbonates.

          1.3 “Integra Process Patents” shall mean United States Patent Numbers 6,120,491, 6,359,102 and
6,620,356 and patents issuing on United States Patent Application Number 10/350,202, together with
all issued foreign counterparts of such patents and patent application, and all issued renewals,
continuations, divisions, patents of addition, reexaminations and/or reissues of such patents or
foreign counterparts.

          1.4 “Second Generation Polycarbonates” shall mean polycarbonates containing sulfur,
phosphorus, chlorine, bromine, boron or iodine atoms or repeat units other than a
desaminotyrosyl-tyrosine alkyl ester and desaminotyrosyl-tyrosine.

          1.5 “Master File” shall mean United States Food and Drug Administration (“FDA”) designated
file MAF-1140 Tyrosine-Derived Polycarbonates, and all amendments and addendums to date, and all
FDA communications of any kind relevant to the same.

          1.6 “End Product” shall mean a product incorporating (i) the First Generation Polycarbonates
in finished product form or (ii) any material whose manufacture would, but for

 

the license granted Rutgers under this Agreement, violate one or more claims of the Integra
Process Patents.

          1.7 “Net Sales” means the total of the gross invoice prices of End Product sold or transferred
by Rutgers, its Affiliates, and its licensees and sublicensees plus rebates and allowances received
by Rutgers, its Affiliates or licensees or sublicensees of amounts that have been deducted from
gross sales less the sum of the following actual and customary deductions (net of rebates or
allowances of such deductions received) included on the invoice and actually paid: cash, trade, or
quantity discounts; sales, use, tariff, or other excise taxes imposed upon particular sales;
import/export duties; and transportation charges. Sales among Rutgers, its Affiliates and its
licensees or sublicensees for ultimate third party use shall be disregarded for purposes of
computing payments under clause 3.1. Payments shall be made only upon sales or transfers between
unrelated third parties and shall be based on arms-length consideration.

     2. Effective Date.

          2.1 This Agreement shall become effective (the “Effective Date”) upon the execution of this
Agreement and both of the following agreements:

               (a) A license from Rutgers to REVA Medical, Inc., a corporation organized under the laws of
the State of California, having a business office at 5751 Copley Drive, San Diego, California
(hereinafter “REVA”) in respect of First Generation Polycarbonates and Second Generation
Polycarbonates for the manufacture, use and sale of vascular devices; and

               (b) An agreement between Integra and REVA providing for payments by REVA to Integra of a fee
per coronary stent sold.

          2.2 Rutgers shall promptly notify Integra in writing when the license described in clause
2.1(a) is executed and Integra shall promptly notify Rutgers in writing when the agreement
described in clause 2.1(b) is executed.

               (a) Promptly following the Effective Date, Integra shall notify in writing, with a copy to
Rutgers, the current manufacturer of tyrosine polymers and advise the manufacturer (1) that
Rutgers, its licensees and its sublicensees have any and all rights necessary to have manufactured
any tyrosine polymers, and (2) to deal directly and exclusively with Rutgers, its licensees and its
sublicensees on a going forward basis, except for winding down Integra’s relationships with the
manufacturer relating to the subject matter of this agreement.

          2.3 The License Agreement shall be terminated and of no further force or effect as of the
Effective Date. As of the Effective Date, Integra irrevocably grants to Rutgers a worldwide
license, with the right to grant sublicenses, to make, have made, use, sell, lease and otherwise
dispose of products employing the Integra Process Patents. The termination of the License
Agreement shall not relieve either party of any obligation or liability accrued thereunder for
royalties,/fees/sublicensing payments or patent costs.

          2.4 Within thirty (30) days following the Effective Date, Integra shall deliver to Rutgers all
tangible documents, information, data and materials described in clause 12.1 of the

2

 

License Agreement, including the Master File and any research data relating to the
biocompatibility of tyrosine polymers, as well as all other materials it has relating to First
Generation Polycarbonates or Second Generation Polycarbonates. Notwithstanding the foregoing,
Integra may retain a copy of such documents and materials for use in rendering such advice as
Rutgers may request pursuant to Section 2.5 hereof. Integra hereby irrevocably assigns to Rutgers
all of its right, title and interest in and to all such tangible documents, information, data and
materials as of the Effective Date.

          2.5 Throughout the term of this Agreement, Integra will provide reasonable assistance,
including, without limitation, the prompt execution of all documents to effect the aforementioned
assignments, to Rutgers in Rutgers’ efforts to effect the transfer of intellectual property,
information, documents, and materials to Rutgers. In addition, Integra will, upon the reasonable
request of Rutgers, provide technical advice to Rutgers on the commercialization of the First
Generation Polycarbonates and the Integra Process Patents and on the Master File during the
three-year period following the date hereof; provided that Integra personnel may render such advice
at times reasonably convenient to Integra and to Rutgers and that Integra shall not be obligated to
devote more than 5 man days to the provision of such advice in the first year following the
execution of this Agreement and no more than two man days in any subsequent year.

     3. Payments.

          3.1 Rutgers shall pay to Integra a portion of any milestone payments and royalties received by
Rutgers from third parties for licensing arrangements made in respect of First Generation
Polycarbonates . The payments shall comprise (i) ***% of milestone payments and of royalties
received by Rutgers until the total amount paid to Integra hereunder exceeds
$*** and (ii) ***% of milestone payments and royalties received by Rutgers
thereafter; but in no case shall the royalties paid to Integra be less than (a) ***% of Net Sales
if End Products contain material whose manufacture would, but for a sublicense granted by Rutgers
or one of its licensees, violate one or more claims of the Integra Process Patents, or (b) ***% of
Net Sales of all other End Products. The agreement between REVA and Rutgers entered into on the
date hereof, and payments received by Rutgers thereunder for use of tyrosines or other materials in
stent, coating and embolotherapy products, shall not be subject to any payments by Rutgers to
Integra under this paragraph 3.1.

          3.2 Rutgers shall deliver to Integra a semi-annual report within thirty (30) days following
the close of any calendar 6 month period in which Rutgers receives a milestone payment or a royalty
under clause 3.1. The report shall set forth the amounts of milestone payments and royalties
received by Rutgers and it shall be accompanied by a check payable to Integra for the amount due.

          3.3 Rutgers shall keep good and accurate books of account sufficient to permit determination
of the payments due hereunder and shall make such books of account available for inspection by an
independent accountant designated by Integra and reasonably acceptable to Rutgers provided that
such accountant executes and delivers to Rutgers a Confidentiality

 

			
	*** 	 	Portions of this page have been omitted
pursuant to a request for Confidential Treatment filed separately with the
Commission.

3

 

Agreement in the form appended as Attachment A hereto. Such inspections shall be no more
frequent than twice each calendar year during the term hereof and once within six months after
termination of this Agreement. The designated accountant shall retain in confidence the
information in the books of account and shall report to Integra only the accuracy or inaccuracy of
the reports rendered pursuant to clause 3.2 hereof. Such inspections will be at Integra’s expense
unless the designated accountant identifies underpayment of royalties due by five percent (5%) or
more in which event Rutgers shall pay for such inspection. Integra’s failure to inspect shall not
constitute a waiver of Integra’s right to object to the accuracy of the reports rendered or
payments made under this Agreement.

          3.4 All underpayments discovered pursuant to clause 3.3, plus interest at the then prevailing
prime interest rate published by Citicorp, New York, New York, U.S.A., on the amount underpaid
shall be promptly paid to Integra; provided, however, that no more than one year’s interest shall
be due on such underpayment.

     4. Term and Termination.

          4.1 This Agreement shall be effective on the Effective Date and shall expire on expiration of
the last to expire of the patents listed on Schedule B hereto unless extended or earlier terminated
pursuant to the terms hereof.

          4.2 This Agreement shall automatically terminate in the event (1) substantially all of the
assets of Integra are seized or attached in conjunction with any action against it by a third
party, or (2) Integra is dissolved or the sale of all or substantially all of its assets is made
other than as part of a merger, or (3) an attempt to assign this Agreement is made without the
prior written consent of Rutgers. Notwithstanding the foregoing this agreement shall be assigned
to any entity into which Integra shall combine or merge.

          4.3 This Agreement may be terminated by either party for a material breach by the other party
of the provisions hereof. Such termination shall be effective thirty (30) days after written
notice to the other party of the breach if the breach has not been remedied.

          4.4 The right of either party to terminate under the provisions of this Article shall not be
an exclusive remedy, and either party shall be entitled, if the circumstances warrant,
alternatively or cumulatively, to damages for breach of this Agreement, to an order requiring
performance of the obligations of this Agreement, or to any other legally available remedy.

          4.5 The following Articles shall survive termination or expiration of this Agreement by their
terms: Articles 1, 2, 3.3, 4.4, 4.5 and 5 through 7.

     5. Representation, Warranties and Covenants.

          5.1 Each party represents, warrants and covenants to the other that:

               (a) It has the full power and authority to execute and deliver this Agreement and perform its
covenants, duties and obligations described in this Agreement; and

4

 

               (b) This Agreement is a valid, legal and binding obligation upon such party, enforceable in
accordance with its terms, except as enforceability may be limited by applicable insolvency and
other laws affecting creditors’ rights generally or by the availability of equitable remedies.

          5.2 Integra represents, warrants and covenants to Rutgers that:

               (a) It is validly existing and in good standing;

               (b) The execution of this Agreement and the full and timely performance of the covenants,
duties and obligations described herein have been duly authorized by all necessary corporate action
in accordance with all applicable laws.

               (c) If Integra becomes aware that on the date hereof it possessed intellectual property or
information in tangible form that (i) is necessary or useful to the commercialization of First
Generation Polycarbonates or Second Generation Polycarbonates or the Integra Process Patents and
(ii) was not assigned or licensed to Rutgers hereby, it will promptly disclose to Rutgers the
existence of such intellectual property or information and either assign without cost or grant a
paid up license with right to sublicense of such intellectual property or information to Rutgers.

               (d) It has good title to the documents, information, data and materials (“Materials”) it is
assigning to Rutgers under Article 2.4, and the Integra Process Patents it is licensing under
Article 2.3, free of all liens and encumbrances. Integra believes that, taken as a whole, the
Materials accurately reflect the findings of the scientists engaged in the development of the
materials. Integra represents that to the best of its knowledge and belief, the Integra Process
Patents do not infringe the intellectual property rights of third parties.

     6. No Assignment.

          6.1 Neither this Agreement, nor any rights or obligations hereunder, may be assigned, pledged
or encumbered by either party without the express prior written approval of the other party.

     7. Miscellaneous.

          7.1 A waiver of any breach of any provision of this Agreement shall not be construed as a
continuing waiver of other breaches of the same or other provisions of this Agreement.

          7.2 Nothing herein shall be deemed to create an agency, joint venture or partnership relation
between the parties hereto.

          7.3 This Agreement and Attachments A and B constitute the sole, entire and final agreement and
understanding of the parties with regard to the subject matter hereof and merges and supersedes all
prior discussions, negotiations, understandings and agreements between the parties concerning the
subject matter hereof. Neither party shall be bound by any definition, condition, warranty, right,
duty or covenant other than as expressly stated in this

5

 

Agreement or as subsequently set forth in a written document signed by both parties. Each
party expressly waives any implied right or obligation regarding the subject matter hereof. A
breach or termination of the Reva/Integra agreement referred to in Article 2.1(b) shall not affect
this Agreement.

          7.4 This Agreement shall be interpreted and construed, and the legal relations created herein
shall be determined, in accordance with the laws of the State of New Jersey (excluding conflict of
laws) and the United States.

          7.5 This Agreement may be amended only by a written document signed by authorized
representatives of both parties.

          7.6 Each party hereto agrees to execute, acknowledge and deliver all such further instruments,
and to do all such further acts, as may be necessary or appropriate to carry out the intent and
purposes of this Agreement.

          7.7 The headings contained in this Agreement are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement.

          7.8 Should any part or provision of this Agreement be held unenforceable or in conflict with
the law of any jurisdiction, the validity of the remaining parts or provisions shall not be
affected by such holding.

          7.9 Any and all notices or other communications required or permitted by this Agreement or by
law to be served on or given to either party hereto by the other party shall be in writing and
delivered or sent to:

Vice President, Technology

Integra LifeSciences Corporation

P.O. Box 688

105 Morgan Lane

Plainsboro, NJ 08536

Rutgers, The State University of New Jersey

Office of Corporate Liaison and Technology Transfer

ASB III, 3 Rutgers Plaza

New Brunswick, New Jersey 08901

Att: Director

     Each party may change its address for purposes of this Agreement by written notice to the
other party.

               (a) Each notice or other communication shall be deemed duly served and given on the date when
personally delivered to the party to whom it is directed, when submitted to a nationally recognized
overnight delivery service, prepaid and addressed to the party at the address in paragraph 7.9, or
when deposited in the United States mail, postage

6

 

prepaid, certified-return receipt requested and addressed tot he party at the address in
paragraph 7.9. When transmitted electronically by telex, facsimile, or e-mail, such notice shall
be deemed duly served and given on the date when the party to whom it is directed confirms receipt
in writing.

          7.10 Upon execution of this agreement, the parties will issue a joint press release announcing
the termination of Integra LifeSciences’ license to Rutgers’ polycarbonates, in form and substance
reasonably acceptable to both parties. Integra will refer current and future inquiries regarding
1st Generation Polycarbonates to Rutgers University.

          7.11 The parties acknowledge and agree that REVA shall be a third party beneficiary to this
Agreement with full rights to enforce its terms.

7

 

          7.12 This Agreement may be executed by each party in duplicate originals, each of which shall be
deemed an original, but both originals together shall constitute only one and the same instrument.

     IN WITNESS WHEREOF, the parties have executed this Agreement in duplicate on the signature
page hereof

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	“Rutgers”
	 
	 	 	 	 	 	 
	 	 	Rutgers, The State University
	 
	 

	 	By: 	 	 	/s/ William T. Adams	 
	 	 	 	 	 
	 

	 	 	Name:	 	William T. Adams	 
	 

	 	 	 	 	 	 
	 

	 	 	Title:	 	Director - OCCTT	 
	 

	 	 	 	 	 	 
	 

	 	 	Date:	 	2-2-04	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	“Integra”
	 
	 	 	 	 	 	 
	 	 	Integra LifeSciences Corporation
	 
	 

	 	By: 	 	 	/s/ John B. Henneman, III	 
	 	 	 	 	 
	 

	 	 	Name:	 	John B. Henneman, III	 
	 

	 	 	 	 	 	 
	 

	 	 	Title:	 	SVP & CAO	 
	 

	 	 	 	 	 	 
	 

	 	 	Date:	 	1/26/04	 
	 	 	 	 	 	 	 

8

 

ATTACHMENT A

CONFIDENTIALITY AGREEMENT

     RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, having its statewide administrative offices at
                                        
(hereafter referred to as “Rutgers”),               
                          , having a
place of business at             
                
             (hereinafter “Accountant”), and Integra
LifeSciences Corporation, a corporation organized under the laws of the State of Delaware, having a
business office at 105 Morgan Lane, Plainsboro, New Jersey 08536 (hereinafter referred to as
“Integra”).

Background

     According to the terms of an Agreement dated                     ,             between Rutgers and Integra
(the “Agreement”), Rutgers is making available to Accountant its books of account as required by
paragraph 3.3 of the Agreement (“CONFIDENTIAL MATERIAL”) for Accountant’s use in preparing a report
to Integra according to the terms of said paragraph 3.3 (the “Report”).

Agreement

     1. Accountant will not use CONFIDENTIAL MATERIAL except to prepare the Report.

     2. Accountant will not disclose CONFIDENTIAL MATERIAL to Integra or any third party and
Accountant shall provide only the Report to Integra and no other party.

     3. Integra shall treat the Report as confidential under the same terms as required for the
treatment of CONFIDENTIAL MATERIAL hereunder and Integra shall not provide the Report or disclose
its contents to any third party.

     4. Integra will limit access to the Report to those employees of Integra who need to know
about or participate in the review of the Report.

     5. CONFIDENTIAL MATERIAL shall remain the property of Rutgers. Sixty (60) days following
completion of the Report, Accountant will return to Rutgers all CONFIDENTIAL MATERIAL in its
possession and destroy all computer entries relating thereto.

     6. The obligations in paragraphs 1 and 2 shall not apply to CONFIDENTIAL MATERIAL:

          (a) which was known to Accountant and was contained in a writing in Accountant’s possession
before its receipt from Rutgers;

          (b) which at the time of its disclosure to Accountant is, or thereafter becomes through no act
or failure to act on the part of Accountant, part of the public domain; or

Attachment A - 1

 

          (c) which has been rightfully furnished to Accountant by a third party without restriction on
disclosure or use and not in violation of any rights of, or obligations to, Rutgers.

     An individual feature of the information shall not be considered within the above exceptions
merely because the feature is embraced by more general information within the exceptions. A
combination of features of the information shall not be considered within the above exceptions
unless the combination itself and its principle of operation are within the exceptions. The
obligation to maintain the secrecy of CONFIDENTIAL MATERIAL and limit its use shall terminate five
(5) years from the date of each disclosure of CONFIDENTIAL MATERIAL hereunder.

     7. This Confidentiality Agreement shall be governed by the laws of the State of New Jersey
without giving effect to the principles of conflict of laws thereof.

     8. This Confidentiality Agreement constitutes the entire agreement among the parties with
respect to the subject matter hereof, and all prior understandings or agreements between the
parties relating to such subject matter, except for the Confidentiality Agreement, whether oral or
written, are automatically cancelled by the execution of this Agreement. The terms and conditions
set forth herein may only be modified I subsequent writing signed by the parties.

     All notices and other communications shall be considered given and effective when personally
delivered or when mailed, postage prepaid, to the addresses set forth on the first page of this
Agreement or to such other addresses as the parties may designate in writing.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	AGREED:	 	 	 	AGREED:
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Rutgers, The State University of New Jersey	 	 	 	Integra LifeSciences Corporation
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	 	 	By:	 	 	 	 
	 	 	 	 	 	 	 	 	   
	 

	 	Name:
	 	 	 	 	 	 	 	Name:	 	 
	 

	 	 	 	 
	 	 	 	 	 	 	 	 
	 

	 	Title:
	 	 	 	 	 	 	 	Title:	 	 
	 

	 	 	 	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 
	AGREED:	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Accountant	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 

Attachment A - 2

 

ATTACHMENT B: SCHEDULE OF PATENTS

COVERING FIRST GENERATION POLYCARBONATES:

US Patent 5,198,507

US Patent 6,120,491 and its international filings listed below:

	 	 	 	 	 	 	 

	 

	 	 	98957728 3	 	 	European PCT
	 

	 	 	2.309,278	 	 	Canadian PCT
	 

	 	 	730549	 	 	Australian PCT
	 

	 	 	2000-520191	 	 	Japan PCT
	 
	 	 	US98/23857	 	 	Mexico

Attachment B - 1

 

Appendix B

INTEGRA TECHNOLOGY

For purposes of clarity, “INTEGRA TECHNOLOGY” does not include inventions, technology, and
intellectual property thereunder, that have reverted or been assigned to RUTGERS pursuant to the
LICENSE TERMINATION AGREEMENT.

     INTEGRA TECHNOLOGY related to “FIRST GENERATION MATERIAL” is defined as the family of
desaminotyrosyl-L-tyrosine derived polycarbonates which include poly(DTE-carbonate),
poly(DTB-carbonate), poly(DTH-carbonate), poly(DTO-carbonate) and po!y(X%DTR-co-Y%DT-carbonate)s
and tyrosine derived polycarbonates containing the chain-terminating groups derived from acetic
anhydride or the ethyl, butyl, hexyl, or octyl esters of L-tyrosine or desamino tyrosine.

Manufacturing

	1.	 	Specific current research, manufacturing and production information for GMP
productions of (poly(DTE carbonate)s not limited to manufacturing standard operating
procedures related to, but not limited to, equipment, purchased raw materials and material
controls, manufacture processes, quality control procedures and characterization of materials.

	2.	 	Specific current research, manufacturing and production information for non-GMP
productions of poly(X%DTE-co-Y%DT carbonate)s) not limited to manufacturing standard operating
procedures related to, but not limited to, equipment, purchased raw materials and material
controls, manufacture processes, quality control procedures and characterization of materials.

	3.	 	Current laboratory methods for:

	 	(a)	 	Conversion of poly(DTE carbonate) to poly(DTE-co-DT carbonate);
	 
	 	(b)	 	Conversion of high to lower molecular weight;
	 
	 	(c)	 	Confirmation of percent DT achieved;
	 
	 	(d)	 	GPC analysis developed by Integra for first generation materials.
	 
	 	(d)	 	And, access to other non-published studies, reports, or methods related to
material characterization of tyrosine polycarbonates.

MAF and Polycarbonate Biocompatibility

	4.	 	Non-published studies and reports represented in summary form in the Master File, FDA
designated file MAF-1140 Tyrosine-Derived Polycarbonates.

Appendix B - 1

 

	5.	 	Non-published studies and reports related to biocompatibility studies for polycarbonates
other than poly(DTE carbonate)s, e.g., poly(DTB carbonate)s, poly(DTH carbonate)s and poly(DTO
carbonate)s.

Patents — Related To Development And Practice Of The Licensed Intention

	6.	 	Integra LifeSciences patent status and access to current, pending and new disclosures related
to developments of the polymers and products related thereto, and new intellectual property
related to FIRST GENERATION MATERIALS, including but not limited to the following patents:

	 	 	 	 	 
	Patent #	 	Title	 	Issuance Date
	US Pat #6,359,102

	 	Biphasic polymerization process
	 	03/19/02
	EP0991693A1

	 	Biphasic polymerization process
	 	04/12/00
	EP0991693B1

	 	Biphasic polymerization process
	 	09/03/03
	US Pat # 6620356

	 	Porous constructs fabricated by gas induced phase inversion
	 	09/16/03

Appendix B - 2

 

APPENDIX C

RUTGERS PATENT RIGHTS

The following rights are included in the definition of RUTGERS PATENT RIGHTS:

THESE PATENTS ARE INCLUDED IN THE DEFINITION OF RUTGERS PATENT RIGHTS ONLY TO THE EXTENT THEY APPLY
TO “POLYCARBONATES”, AS DEFINED AT THE END OF THIS APPENDIX:

     A. U.S. Patent 6,475,477B1 “Radio-opaque Polymer Biomaterials.”

     B. US Patent 5,099,060 “Synthesis of amino acid-derived bioerodible polymers.” This patent is
included only to the extent that the patented monomers are used in the fabrication of
POLYCARBONATES.

     C. US Patent 5,587,507 “Synthesis of tyrosine derived diphenol monomers.” This patent is
included only to the extent that the monomers produced thereby are used in the fabrication of
POLYCARBONATES.

     D. US Patent 5,658,995 “Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide).”

     E. US Patent 6,048,521 “Copolymers of tyrosine-based polyarylates and poly(alkylene oxide).”

     F. US Patent 6,319,492 B1 “Copolymers of tyrosine-based polyarylates and poly(alkylene
oxide)”.

     G. US Patent 5,198,507 “Synthesis of amino acid-derived bioerodible polymers”.

     H. US Patent 6,120,491 “Biodegradable, anionic polymers derived from the amino acid
L-tyrosine.”

     I. US Patent 6,359,102 issued on March 19, 2002, “Biphasic polymerization process, EP0991693A1
issued on April 12, 2000, “Biphasic polymerization process,” and EP0991693B issued on September
3,2003, “Biphasic polymerization process.”

     J. US Patent 6,620,356 issued on September 16, 2003, “Porous constructs fabricated by gas
induced phase inversion.”

     K. Rutgers Docket 03-175.

“POLYCARBONATES” means tyrosine-derived polymers containing desaminotyrosyl-tyrosine or
desaminotyrosyl-tyrosine alkyl ester repeat units linked together by carbonate backbone linkages as
described in subsections (a) through (e) below and which comprise a subgroup of the polymers
defined by the comprehensive chemical Formula VIII listed under CLAIM 1 in US Patent 6,475,477B1.
POLYCARBONATES exclude all polymers commonly referred to as

Appendix C - 1

 

polyarylates. With reference to said Formula VIII, for the purposes of this License Agreement, a
POLYCARBONATE is a polymer that meets all the following conditions:

a. “A” described in said Formula VIII is limited to being a simple carbonyl group, e.g., carbon
double bonded to oxygen as indicated by Structure 1; AND

(Structure 1)

b. XI and X2 in said Formula VIII are independently Iodine or Bromine atoms; Y1 and Y2 in said
Formula VIII are independently 0, 1, or 2. Non-radio-opaque polymers are obtained if both Y1 and
Y2 are equal to zero (0); AND

c. R7 in said Formula VIII is independently an alkylene group containing up to 4 carbon atoms
(e.g., methylene, ethylene, propylene, or butylene); AND

d. R9 and R12 in said Formula VIII are limited by the requirements that

(i) R4 equals (-CH2-) with subscript “a” equals 2 as defined in Claim 3 of said US patent

(ii) R0 equals (-CH2-) with subscript “m” equals 1 as defined in Claim 3 of said US patent

(iii) Z in Claim 3 is limited to a free carboxylic acid group or carboxylic acid esters or amides
having straight or branched alkyl and alkyl aryl groups containing up to 18 carbon atoms, or esters
and amides of biologically and pharmaceutically active compounds; AND

e. The parameter “f” in said Formula VIII can vary from 0 to 0.99 (including the values of “0” and
“0.99”). The parameter “g” in said Formula VIII can vary from 0 to 1 (including the values of “0”
and “1”). The parameter “k” in said Formula VIII is between 5 and 3,000.

Said definition of POLYCARBONATE contains as a subgroup, but is not limited to the polymers
exemplified by Formula 1 which is shown here for illustrative purposes only. In Formula 1, the I
stands for iodine, DTR stands for desaminotyrosyl-tyrosine alkyl ester, DT Stands for
desaminotyrosyl-tyrosine, and PEG stands for poly(ethylene glycol);

Formula 1. poly(IxDTR-co-f%PEGmw-co-g%DT carbonate)

One potential embodiment of Formula 1. further exemplified is:

poly(I2DTE-co-5%PEG1000-co-30%DT carbonate).

Appendix C - 2

 

APPENDIX D

Reva/Integra License Agreement Royalty Report for the Period                      Through                     

Instructions: Please fill in all boxes (write “none” if not applicable), and sign and date at
bottom. All section numbers refer to the License Agreement.

Answer questions 1 and 2 (AND SIGN AND DATE AT BOTTOM) EVEN IF THERE HAS BEEN NO ACTIVITY in
reporting period.

	1.	 	Number of transactions: by REV A o
 by  Sublicensees o
	 
	2.	 	Any new sublicenses entered into during the period? Yes 
o no o

If yes, attach separate sheet listing names and addresses of sublicensees, and attach sublicense
agreements.

Total
amount enclosed $                                         

REVA Medical, Inc.

	 	 	 	 	 	 	 

	 	 	Date:  	 	 	 	 

	 	 	 	 	 

	Name and Title:  	 	 	 	 

Appendix D - 1 

 

APPENDIX D (Continued)

Continuation sheet number              to REVA/INTEGRA License Agreement Royalty Report for the Period
              through 
            

Use this sheet if there are additional transactions to report.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	By ____ or	 	 	Product or Process	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Date of	 	 	 	 	 	 	Sublicense? (if	 	 	Type (name and id	 	 	 	 	 	 	Deductions per § __	 	 	 	 	 	 	 
	Transaction	 	 	Type of Transaction	 	 	latter, identify)	 	 	number)	 	 	Total Billings	 	 	(specify type)	 	 	Royalties Due	 	 	Customer Name and Address	 

Appendix D - 2Exhibit 4.2

 

 

REGISTRATION
RIGHTS AGREEMENT

 

By and Among

 

NetSpend Holdings, Inc.,

 

NetSpend Corporation,

 

and

 

The Stockholders, as defined
herein,

 

 

Dated as of
                
      , 2010

 

 

 

TABLE OF CONTENTS

 

	
  REGISTRATION RIGHTS AGREEMENT

  	
  1

  
	
   

  	
   

  
	
  ARTICLE I DEFINITIONS

  	
  1

  
	
   

  	
   

  
	
  SECTION 1.1.

  	
  CONSTRUCTION OF TERMS

  	
  1

  
	
  SECTION 1.2.

  	
  NUMBER OF SHARES OF STOCK

  	
  1

  
	
  SECTION 1.3.

  	
  DEFINED TERMS

  	
  2

  
	
   

  	
   

  	
   

  
	
  ARTICLE II REGISTRATION RIGHTS

  	
  4

  
	
   

  	
   

  
	
  SECTION 2.1.

  	
  DEMAND REGISTRATION

  	
  4

  
	
  SECTION 2.2.

  	
  PIGGYBACK REGISTRATION

  	
  7

  
	
  SECTION 2.3.

  	
  FURTHER OBLIGATIONS OF THE COMPANY

  	
  7

  
	
  SECTION 2.4.

  	
  INDEMNIFICATION; CONTRIBUTION

  	
  10

  
	
  SECTION 2.5.

  	
  RULE 144 AND RULE 144A

  	
  11

  
	
  SECTION 2.6.

  	
  MOST FAVORED NATIONS

  	
  11

  
	
  SECTION 2.7.

  	
  MERGERS, ETC.

  	
  12

  
	
  SECTION 2.8.

  	
  NO CONFLICT OF RIGHTS

  	
  12

  
	
   

  	
   

  	
   

  
	
  ARTICLE III GENERAL

  	
  12

  
	
   

  	
   

  
	
  SECTION 3.1.

  	
  AMENDMENTS, WAIVERS AND CONSENTS

  	
  12

  
	
  SECTION 3.2.

  	
  GOVERNING LAW

  	
  13

  
	
  SECTION 3.3.

  	
  SECTION HEADINGS

  	
  13

  
	
  SECTION 3.4.

  	
  COUNTERPARTS

  	
  13

  
	
  SECTION 3.5.

  	
  NOTICES AND DEMANDS

  	
  13

  
	
  SECTION 3.6.

  	
  SUBMISSION TO JURISDICTION; VENUE

  	
  13

  
	
  SECTION 3.7.

  	
  REMEDIES; SEVERABILITY

  	
  14

  
	
  SECTION 3.8.

  	
  WAIVER OF JURY TRIAL

  	
  14

  
	
  SECTION 3.9.

  	
  INTEGRATION; EFFECTIVENESS

  	
  14

  
	
  SECTION 3.10.

  	
  SUCCESSORS AND ASSIGNS

  	
  14

  
	
  SECTION 3.11.

  	
  FURTHER ASSURANCES

  	
  14

  
	
  SECTION 3.12.

  	
  TERM

  	
  14

  
	
  SECTION 3.13.

  	
  JOINDER AGREEMENT

  	
  15

  
	
   

  	
   

  	
   

  
	
  SCHEDULE I - STOCKHOLDERS

  	
   

  

 

i

 

REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION RIGHTS
AGREEMENT (the “Agreement”) is
made as of
                  
      , 2010 by and among (i) NetSpend
Holdings, Inc., a Delaware corporation (together with any successor
thereto, the “Company”); (ii) NetSpend Corporation, a Delaware
corporation and a wholly-owned subsidiary of the Company (“NetSpend”);
and (iii) the stockholders identified on Schedule I hereto
(together with any stockholders who join as parties pursuant to Section 3.13
of this Agreement, the “Stockholders” and each a “Stockholder”).

 

RECITALS

 

WHEREAS, the parties hereto are parties to that certain Amended and Restated
Stockholders’ Agreement, dated as of July 15, 2008, as amended (the “Stockholders’
Agreement”);

 

WHEREAS, pursuant to Section 6.14 of the Stockholders’ Agreement,
certain provisions thereof are terminated effective upon the closing of the
Company’s Initial Public Offering (as defined in the Stockholders’ Agreement);

 

WHEREAS, the Company has filed a registration statement on Form S-1 for
the initial public offering of its Common Stock (the “IPO”), which will
constitute an Initial Public Offering for purposes of the Stockholders’
Agreement; and

 

WHEREAS, the Company and the requisite parties desire to amend and restate the
Stockholders’ Agreement in its entirety effective upon the closing of the IPO
in order to (i) eliminate the provisions that terminate upon the
consummation of the IPO in accordance with Section 6.14 of the
Stockholders Agreement, (ii) rename the Stockholders’ Agreement a “Registration
Rights Agreement” and (iii) make certain other amendments to the
Stockholders Agreement, which agreement is evidenced by their execution hereof.

 

AGREEMENT

 

NOW THEREFORE, in consideration of the foregoing and the mutual covenants and
agreements hereinafter set forth, the parties hereto agree as follows:

 

ARTICLE I

 

DEFINITIONS

 

Section 1.1.           Construction of Terms.  As
used herein, the masculine, feminine or neuter gender, and the singular or
plural number, shall be deemed to be or to include the other genders or number,
as the case may be, whenever the context so indicates or requires.  The word “including” as used herein shall be
deemed to mean “including without limitation.”

 

Section 1.2.           Number of Shares of Stock.  Whenever any provision of the Agreement calls for any calculation based
on a number of shares of Common Stock held by a Stockholder, the number of
shares deemed to be held by a Stockholder shall be (i) the total number of
shares of Common Stock then owned by such Stockholder, plus (ii) the total
number of shares of Common Stock issuable upon conversion of any convertible
securities of the Company or 

 

1

 

exercise of any options, warrants or subscription
rights granted or issued by the Company then owned by such Stockholder (all on
an as exercised and/or as converted basis).

 

Section 1.3.           Defined Terms. 
The following capitalized terms, as used in
this Agreement, shall have the meanings set forth below:

 

“Agreement”
shall have the meaning set forth in the Preamble.

 

“automatic shelf
registration statement” shall have the meaning set forth in Section 2.3(b).

 

“Board of Directors”
means the Board of Directors of the Company.

 

“Calculated on a fully
diluted basis” means, when used with reference to Common Stock,
calculated on a pro forma basis assuming the conversion and exchange of all
securities convertible into or exchangeable for shares of Common Stock, and the
exercise of all options, warrants and other rights to purchase shares of Common
Stock or such convertible or exchangeable securities.

 

“Commission”
means the Securities and Exchange Commission.

 

“Common Stock” means the Common Stock, par value $0.001 per share, of the Company, and
any other shares of stock issued or issuable with respect thereto (whether by
way of a stock dividend or stock split or in exchange for or in replacement of
or upon conversion of such shares or otherwise in connection with a combination
of shares, recapitalization, merger, consolidation or other corporate
reorganization).

 

“Company”  shall have the meaning set
forth in the Preamble.

 

“Controlling Person”
shall have the meaning set forth in Section 2.4(a)(i).

 

“Damages”
shall have the meaning set forth in Section 2.4(a)(i).

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

 

“Form S-3 Registration”
shall have the meaning set forth in Section 2.1(b).

 

“Holders”
means Stockholders holding Registrable Securities.

 

“Initial Public Offering”
means the first firm commitment underwritten public offering for shares of
Common Stock pursuant to an effective registration statement under the
Securities Act with aggregate gross proceeds of at least $25,000,000.

 

“Investor”  and “Investors”  shall have the meaning set forth in
the Preamble.

 

“JLL” means
Skylight Holdings until such time as JLL Partners Fund V, L.P. and JLL Partners
Fund IV, L.P. have executed a Joinder Agreement, and thereafter Skylight
Holdings, JLL Partners Fund V, L.P. and JLL Partners Fund IV, L.P.

 

2

 

“JLL Investors”
means JLL and the equityholders of Skylight Holdings as of the date hereof.

 

“NetSpend”  shall have the meaning set
forth in the Preamble.

 

“Oak Investors”
means Oak Investment Partners X Fund, Limited Partnership and Oak X Affiliates
Fund, L.P.

 

“Person”
means an individual or group of individuals, a corporation, an association, a
partnership, a limited or general limited liability company, an estate, a
trust, and any other entity or organization, governmental or otherwise.

 

“Registrable Securities”
means (i) any shares of Common Stock held by a Stockholder (as determined
in accordance with Section 1.2 hereof) and (ii) any securities
issued and issuable with respect to any such shares described in clause (i) above
by way of a stock dividend or stock split or in connection with a combination
of shares, recapitalization, merger, consolidation or other reorganization; provided,
however, that notwithstanding anything to the contrary contained herein,
“Registrable Securities” shall not include at any time securities (a) sold
in a registered sale pursuant to an effective registration statement under the
Securities Act, (b) sold to the public pursuant to Rule 144 under the
Securities Act, (c) which could be sold pursuant to Rule 144 (or any
successor rule) under the Securities Act without limitation or restriction, (d) which
could be sold completely by any owner thereof within a three (3) month
period under provisions of Rule 144 under the Securities Act or (e) sold
in a private transaction in which the Transferee’s rights under Article II
of this Agreement are not assigned.

 

“S-3 Stockholders”
shall have the meaning set forth in Section 2.1(b).

 

“Securities Act”
means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.

 

“Securities”
means Common Stock and any other shares of capital stock of the Company, and
any securities convertible into or exchangeable for such capital stock, and any
options (including options issued to Stockholders), warrants or other rights to
acquire such capital stock or securities of the Company, now or hereafter held
by any party hereto, including all other securities of the Company (or a
successor to the Company) received on account of ownership of Common Stock,
including all securities issued in connection with any merger, consolidation,
stock dividend, stock distribution, stock split, reverse stock split, stock
combination, recapitalization, reclassification, subdivision, conversion or
similar transaction in respect thereof.

 

“Selling Holder”
shall have the meaning set forth in Section 2.4(a)(i).

 

“Significant Stockholder” means each Stockholder (i) that holds in excess of 450,000 shares
of Common Stock (such number to be adjusted to reflect any reclassification,
stock split, reverse stock split or similar transaction which changes the
number of outstanding shares of Common Stock after the date hereof) and (ii) is
an “accredited investor” as defined in Rule 501(a) of Regulation D
under the Securities Act; provided that, for purposes of the definition of
Significant Stockholder, the JLL Investors shall be deemed to be a single
stockholder.

 

3

 

“Skylight Holdings” means Skylight
Holdings I, LLC.

 

“Stockholder” and
“Stockholders”
shall have the meaning set forth in the Preamble.

 

“Transfer”
means any direct or indirect transfer, donation, sale, assignment, pledge,
hypothecation, grant of a security interest in or other disposal of all or any
portion of a Security or of any rights thereunder

 

“Transferee”
means the recipient of a Transfer.

 

“WKSI” shall
have the meaning set forth in Section 2.3(b).

 

ARTICLE II

 

REGISTRATION RIGHTS

 

Section 2.1.           Demand Registration.

 

(a)   Oak
Investor and JLL Investor Demand Registration Rights.

 

(i)            At
any time after the date that is one hundred eighty (180) days after the Initial
Public Offering pursuant to an effective registration statement under the
Securities Act (or such earlier time that any applicable “underwriters’ lock-up”
is terminated or waived), the Oak Investors may request that the Company
register under the Securities Act at least 15% of the Registrable Securities
held by the Oak Investors. 
Notwithstanding the foregoing, (i) if the Board of Directors
determines in good faith that any such registration would be materially
detrimental to the Company, the Company may defer such registration for no more
than one hundred twenty (120) days in any twelve (12) month period and (ii) the
Company shall not be obligated to effect such a registration during any period
beginning sixty (60) days prior to the estimated filing date and ending one
hundred and eighty (180) days after the effective date of any registration
statement under the Securities Act registering the offer and sale of shares of
Common Stock by the Company.

 

(ii)           At
any time after the date that is one hundred eighty (180) days after the Initial
Public Offering pursuant to an effective registration statement under the
Securities Act (or such earlier time that any applicable “underwriters’ lock-up”
is terminated or waived), JLL may request that the Company register under the
Securities Act at least 15% of the Registrable Securities held by the JLL
Investors.  Notwithstanding the
foregoing, (i) if the Board of Directors determines in good faith that any
such registration would be materially detrimental to the Company, the Company
may defer such registration for no more than one hundred twenty (120) days in
any twelve (12) month period and (ii) the Company shall not be obligated
to effect such a registration during any period beginning sixty (60) days prior
to the estimated filing date and ending one hundred and eighty (180) days after
the effective date of any registration statement under the Securities Act
registering the offer and sale of shares of Common Stock by the Company.

 

(iii)          If
a requested registration pursuant to this Section 2.1(a) involves
an underwritten public offering and if the underwriter(s) determines that
marketing factors require a limitation on the number of Registrable Securities
to be offered, the Company shall not be required to register Registrable
Securities of the Holders in excess of the amount, if any, of 

 

4

 

shares
of the capital stock which the principal underwriter of such underwritten
offering shall reasonably and in good faith agree to include in such offering
in addition to any amount to be registered for the account of the Company.  If any limitation of the number of shares of
Registrable Securities to be registered by the Holders is required pursuant to
this Section 2.1(a)(iii), the number of shares to be excluded shall
be determined in the following sequence (i.e., the shares listed first will be
excluded first):  (1) first, shares
of Common Stock held by any Persons not having contractual, piggyback
registration rights, (2) second, shares of Common Stock held by any
Persons (other than Holders) having contractual, piggyback registration rights
other than those set forth in Section 2.2, (3) third, the
Registrable Securities sought to be included by Holders thereof under Section 2.2,
but not including either the Oak Investors or the JLL Investors in the case of
a registration by the Company made pursuant to a registration demand of either
the Oak Investors or JLL under this Section 2.1, as determined on a
pro rata basis (based upon the respective number of Registrable Securities
requested by each Holder to be included in such registration), (4) fourth,
shares of Common Stock held by the Oak Investors and the JLL Investors in the
case of a registration by the Company made pursuant to a registration demand
registration of either the Oak Investors or JLL under this Section 2.1
(based upon the respective number of Registrable Securities requested by each
such Holder to be included in such registration), and (5) fifth, shares of
Common Stock to be sold by the Company.

 

(b)   Form S-3
Registration.

 

(i)            After
the Company’s Initial Public Offering, the Company shall use its best efforts
to qualify and remain qualified to register securities on Form S-3 (or any
successor form) under the Securities Act. 
So long as the Company is qualified to register securities on Form S-3
(or any successor form), any Significant Stockholder (collectively, the “S-3
Stockholders”) shall have the right to request on any number of occasions
registration on Form S-3 (or any successor form) for the Registrable
Securities having anticipated gross proceeds of at least at $500,000 held by
such S-3 Stockholders, including registrations for the sale of such Registrable
Securities on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act; provided, however, that the Company will only be
required to file two (2) such Form S-3 registrations in any twelve
(12) month period (a “Form S-3 Registration”).  Notwithstanding the foregoing, (A) if
the Board of Directors determines in good faith that any such registration
would be materially detrimental to the Company, the Company may defer such
registration for no more than ninety (90) days in any twelve (12) month period,
and (B) the Company shall not be obligated to effect such a registration
during any period beginning sixty (60) days prior to the estimated filing date
and ending one hundred and eighty (180) days after the effective date of any
registration statement under the Securities Act registering the offer and sale
of shares of Common Stock by the Company (other than a registration statement
on Form S-4 or Form S-8, to which this clause (B) shall not
apply).

 

(ii)           Following
a request pursuant to Section 2.1(b)(i) above, the Company
will notify all of the Holders who would be entitled to notice of a proposed
registration under Section 2.2 below and any other holder of
piggyback registration rights of its receipt of such notification from an S-3
Stockholder(s).  Upon the written request
of any such Holder or other holder of the Company’s Securities delivered to the
Company within twenty (20) days after receipt from the Company of such
notification, the Company will either (i) elect to make a primary
offering, in which case the rights of such Holders shall be as set forth in Section 2.2

 

5

 

below
(in which case the registration shall not count as of the S-3 Stockholders’
permitted Form S-3 Registration hereunder), or (ii) use its best
efforts to cause such of the Registrable Securities as may be requested by any
Holders and any other holders of piggyback registration rights to be registered
under the Securities Act in accordance with the terms of this Section 2.1(b).  If the request for registration contemplates
an underwritten public offering, the Company shall state such in the written
notice and in such event the right of any Person to participate in such
registration shall be conditioned upon their participation in such underwritten
public offering and the inclusion of their Securities in the underwritten
public offering to the extent provided herein.

 

(iii)          If
a requested registration pursuant to this Section 2.1(b) involves
an underwritten public offering and the managing underwriter of such offering
determines in good faith that the number of securities sought to be offered
should be limited due to market conditions, then the number of securities to be
included in such underwritten public offering shall be reduced to a number
deemed satisfactory by such managing underwriter, provided that the shares to
be excluded shall be determined in the following sequence (i.e., the shares
listed first will be excluded first):  (1) first,
shares of Common Stock held by any other Persons (other than the Holders of
Registrable Securities) having a contractual, piggyback right to include such
securities in the registration statement, (2) second, shares sought to be
registered by the Company and (3) third, Registrable Securities of Holders
(based upon the respective number of Registrable Securities requested by each
Holder to be included in such registration). 
If there is a reduction of the number of Registrable Securities pursuant
to clause (3), such reduction shall be made on a pro rata basis (based upon the
aggregate number of shares of Registrable Securities held by each such Holder
(calculated in accordance with Section 1.2 above)), and, if the
number of Holders’ Registrable Shares included in such registration is reduced
by 25% or more of the number requested for registration, the registration shall
not count as the S-3 Stockholders’ permitted Form S-3 Registration
hereunder.

 

(iv)          The
Company may postpone the filing of any registration statement required under
this Section 2.1(b) for a reasonable period of time, not to
exceed ninety (90) days in the aggregate during any twelve (12) month period,
if the Company has been advised by legal counsel that such filing would require
a special audit or the disclosure of a material impending transaction or other
matter and Board of Directors determines reasonably and in good faith that such
disclosure would have a material adverse effect on the Company.  The Company shall not be required to cause a
registration statement requested pursuant to this Section 2.1(b) to
become effective prior to one hundred eighty (180) days following the effective
date of a registration statement initiated by the Company if the request for
registration has been received by the Company subsequent to the giving of
written notice by the Company, made in good faith, to the S-3 Stockholders that
the Company is commencing to prepare a Company-initiated registration statement
(other than a registration effected solely to implement an employee benefit
plan or a transaction to which Rule 145 or any other similar rule under
the Securities Act is applicable); provided, however, that the
Company shall use its best efforts to achieve such effectiveness promptly
following such period.

 

(c)   Participation
in Underwritten Offerings.  No Holder
may participate in any underwritten offering hereunder unless such Holder (i) agrees
to sell such Holder’s Common Stock on the basis provided in any underwriting
arrangements approved by the persons who have selected the underwriter (it
being understood any such arrangements shall be customary for 

 

6

 

registered
secondary offerings) and (ii) accurately completes in a timely manner and
executes all questionnaires, powers of attorney, underwriting agreements and
other documents customarily required under the terms of such underwriting
arrangements; provided,  however,
that no Holder will be required to provide representations and warranties or
indemnities in any such underwriting agreement that are not customary for
investors of its type in such transaction. 
The underwriter for any underwritten registration pursuant to this Section 2.1
shall be selected by the holders of a majority of the Registrable Securities
being registered and shall be reasonably acceptable to the Company.

 

Section 2.2.           Piggyback Registration.  If, at any time or times
following the effective date of this Agreement, the Company shall seek to
register any shares of Common Stock under the Securities Act for offer or sale
to the public, whether for its own account or for the account of others (except
with respect to registration statements on Form S-4, S-8 or another form
not available for registering the Registrable Securities for sale, but
expressly including a Form S-3 Registration pursuant to Section 2.1(b) above),
the Company will promptly give written notice thereof to the Holders.  If within twenty (20) days after their
receipt of such notice, one or more Holder or Holders request the inclusion of
some or all of the Registrable Securities owned by them in such registration,
the Company will use best efforts to effect the registration under the
Securities Act of the offer and sale of all such Registrable Securities.  The Holders’ registration rights arising
under this Section 2.2 as a result of any registration pursuant to Section 2.1
shall be subject to the conditions, obligations and limitations provided in Section 2.1
related to such registration.

 

Section 2.3.           Further Obligations of the Company.

 

(a)   General
Obligations Upon Registration. 
Whenever the Company is required hereunder to register any Registrable
Securities, it agrees that it shall also do the following:

 

(i)            Pay
all expenses of such registrations and offerings (exclusive of underwriting
discounts and commissions) and the reasonable fees and expenses of not more
than one independent counsel for the Holders or the S-3 Stockholders (as the
case may be) (as satisfactory to the Holders or the S-3 Stockholders (as the
case may be) holding not less than 50.1% of the Registrable Securities being
registered thereby) in connection with any registrations pursuant to Sections
2.1(a), 2.1(b) or 2.2;

 

(ii)           Use
its best efforts diligently to prepare and file with the Commission a
registration statement and such amendments and supplements to said registration
statement and the prospectus used in connection therewith as may be necessary
to keep said registration statement effective until the Holder(s) or the
S-3 Stockholder(s) (as the case may be) have completed the distribution
described in the registration statement relating thereto (but for no more than
nine (9) months) and to comply with the provisions of the Securities Act
with respect to the sale of securities covered by said registration statement
for such period;

 

(iii)          Furnish
to each selling Holder or the S-3 Stockholder (as the case may be) such copies
of each preliminary and final prospectus and such other documents as such
Holder or S-3 Stockholder may reasonably request to facilitate the public
offering of his, her or its Registrable Securities;

 

7

 

(iv)          Enter
into any reasonable underwriting agreement required by the proposed
underwriter, if any, in such form and containing such terms as are customary; provided,
however, that no Holder or S-3 Stockholder (as the case may be) shall be
required to make any representations or warranties other than with respect to
his, her or its title to the Registrable Securities and with respect to any
written information provided by the Holder or the S-3 Stockholder to the
Company specifically for use in the registration statement, and if the
underwriter requires that representations or warranties be made and that
indemnification be provided, the Company shall make all such representations
and warranties and provide all such indemnities, including, without limitation,
in respect of the Company’s business, operations and financial information and
the disclosures relating thereto in the prospectus;

 

(v)           Use
its best efforts to register or qualify the securities covered by said
registration statement under the securities or “blue sky” laws of such
jurisdictions as any selling Holder or S-3 Stockholder (as the case may be) may
reasonably request; provided, that the Company shall not be required to
register or qualify the securities in any jurisdictions in which such
registration or qualification would require it to qualify to do business
therein;

 

(vi)          Immediately
notify each selling Holder or S-3 Stockholder (as the case may be), at any time
when a prospectus relating to his, her or its Registrable Securities is
required to be delivered under the Securities Act, of the happening of any
event as a result of which such prospectus contains an untrue statement of a
material fact or omits any material fact necessary to make the statements
therein not misleading, and, at the request of any such selling Holder or S-3
Stockholder, prepare a supplement or amendment to such prospectus so that, as
thereafter delivered to the purchasers of such Registrable Securities, such
prospectus will not contain any untrue statement of a material fact or omit to
state any material fact necessary to make the statements therein, in the light
of the circumstances under which such statements were made, not misleading;

 

(vii)         Cause
all such Registrable Securities to be listed on each securities exchange or
quotation system on which similar securities issued by the Company are then
listed or quoted;

 

(viii)        Otherwise
use its best efforts to comply with the securities laws of the United States
and other applicable jurisdictions and all applicable rules and regulations
of the Commission and comparable governmental agencies in other applicable
jurisdictions and make generally available to its stockholders, in each case as
soon as practicable, but not later than forty five (45) days after the close of
the period covered thereby, an earnings statement of the Company which will
satisfy the provisions of Section 11(a) of the Securities Act;

 

(ix)           Obtain
and furnish to each selling Holder or S-3 Stockholder (as the case may be),
immediately prior to the effectiveness of the registration statement (and, in
the case of an underwritten offering, at the time of delivery of any
Registrable Securities sold pursuant thereto), a comfort letter from the
Company’s independent public accountants in customary form and covering such
matters of the type customarily covered by cold comfort letters as the Holders
or the S-3 Stockholders of a majority of the Registrable Securities being sold
may reasonably request; and

 

8

 

(x)                                 Otherwise cooperate with the underwriter or
underwriters, the Commission and other regulatory agencies and take all actions
and execute and deliver or cause to be executed and delivered all documents
necessary to effect the registration of any Registrable Securities under this Article II.

 

(b)         Shelf Registration.

 

(i)                                     To the extent the Company is a well-known
seasoned issuer (as defined in Rule 405 under the Securities Act) (a “WKSI”)
at the time any request for registration pursuant to Section 2.1 or
2.2 is submitted to the Company, and such request for registration
requests that the Company file an automatic shelf registration statement (as
defined in Rule 405 under the Securities Act) (an “automatic shelf
registration statement”) on Form S-3 or any comparable or successor
form, the Company shall file an automatic shelf registration statement which
covers those Registrable Securities which are requested to be registered, all
in accordance with the provisions of Section 2.1 or 2.2.  If the Company does not pay the filing fee
covering Registrable Securities at the time such automatic shelf registration
statement is filed, the Company agrees to pay such fee at such time or times as
the Registrable Securities are to be sold. 
If at any time when the Company is required to re-evaluate its WKSI
status, the Company determines that it is not a WKSI, the Company shall use its
commercially reasonable efforts to refile the shelf registration statement on Form S-3
or any comparable or successor form and, if such form is not available, Form S-1
or any comparable or successor form, and keep such registration statement
effective during the period during which such registration statement is
required to be kept effective.

 

(ii)                                  If the Company is a WKSI at the time it files
any shelf registration statement for the benefit of the holders of any of its
securities other than the Holders, the Company agrees that it shall use its
commercially reasonable efforts to include in such registration statement such
disclosures as may be required by Rule 430B under the Securities Act
(referring to the unnamed selling security holders in a generic manner by
identifying the initial offering of the securities to the Holders) in order to
ensure that the Holders may be added to such shelf registration statement at a
later time upon exercise of their rights pursuant to Section 2.1(b) through
the filing of a prospectus supplement rather than a post-effective amendment.

 

(c)          Deemed Underwriters.  To the
extent that, in connection with a registration of any of the Registrable
Securities under the Securities Act pursuant to Section 2.1 or 2.2,
any selling Holder is deemed to be an underwriter of Registrable Securities
pursuant to any Commission comments or policies, the Company agrees that (1) the
indemnification and contribution provisions contained in Section 2.4
shall be applicable to the benefit of the selling Holders in their role as
deemed underwriter in addition to their capacity as Holder and (2) the
selling Holders shall be entitled to conduct the due diligence which they would
normally conduct in connection with an offering of securities registered under
the Securities Act, including without limitation receipt of customary opinions
and comfort letters.

 

9

 

Section 2.4.                                Indemnification;
Contribution.

 

(a)         Indemnification.

 

(i)                                     Incident to any registration statement
referred to in this Article II, the Company will indemnify and hold
harmless each underwriter, each Holder and S-3 Stockholder who offers or sells
any such Registrable Securities in connection with such registration statement
(including its partners (including partners of partners and stockholders of any
such partners), and members, managers, directors, officers, employees and agents
of any of them (a “Selling Holder”), and each person who controls any of
them within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act (a “Controlling Person”), from and against any and
all losses, claims, damages, liabilities, costs and expenses (including any
investigation, legal and other expenses incurred in connection with, and any
amount paid in settlement of, any action, suit or proceeding or any claim
asserted, as the same are incurred) (collectively, the “Damages”), joint
or several, to which they, or any of them, may become subject under the
Securities Act, the Exchange Act or other federal or state statutory law or
regulation, at common law or otherwise, insofar as such Damages arise out of or
are based on (A) any untrue statement or alleged untrue statement of a
material fact contained in such registration statement (including any related
preliminary or definitive prospectus, or any amendment or supplement to such
registration statement or prospectus), (B) any omission or alleged
omission to state in such document a material fact required to be stated in it
or necessary to make the statements therein, in the light of the circumstances
under which such statements were made, not misleading, or (C) any
violation by the Company of the Securities Act, any state securities or “blue
sky” laws or any rule or regulation thereunder in connection with such
registration; provided, however, that the Company will not be liable to the
extent that such Damages arise from and are based on an untrue statement or
omission or alleged untrue statement or omission made in reliance on and in
conformity with information furnished in writing to the Company by such
underwriter, Selling Holder or Controlling Person expressly for use in such registration
statement.

 

(ii)                                  With respect to any such untrue statement or
omission or alleged untrue statement or omission in the information furnished
in writing to the Company by such Selling Holder expressly for use in any
registration statement referred to in this Article II, such Selling
Holder will, severally and not jointly, indemnify and hold harmless each
underwriter, the Company (including its directors, officers, employees and
agents), each other Holder and S-3 Stockholder (including its partners (including
partners of partners and stockholders of such partners) and members, managers,
directors, officers, employees and agents of any of them, and each person who
controls any of them within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act), from and against any Damages,
joint or several, to which they, or any of them, may become subject under the
Securities Act, the Exchange Act or other federal or state statutory law or
regulation, at common law or otherwise to the same extent provided in the
immediately preceding sentence.  In no
event, however, shall the liability of a Selling Holder for indemnification
under this Section 2.4(a)(ii) exceed the net proceeds received
by such Selling Holder from its, his or her sale of Registrable Securities
under such registration statement.

 

(b)         Contribution.  If the
indemnification provided for in Section 2.4(a) above for any
reason is held by a court of competent jurisdiction to be unavailable to an
indemnified party in respect of any Damages referred to therein, then each
indemnifying party under this Section 2.4, in lieu of indemnifying
such indemnified party thereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such Damages (i) in such
proportion as is appropriate to reflect the relative benefits received by the
Company, the other Selling Holders 

 

10

 

and
the underwriters from the offering of the Registrable Securities or (ii) if
the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i) above but also the relative fault of
the Company, the other Selling Holders and the underwriters in connection with
the statements or omissions which resulted in such Damages, as well as any
other relevant equitable considerations; provided, however, that
in the event of a registration statement filed in response to a request under Section 2.1(b),
the proportion of contribution by the Company, the other Selling Holders and
the underwriters shall in all cases be governed by clause (ii) above.  The relative benefits received by the
Company, the Selling Holders and the underwriters shall be deemed to be in the
same respective proportions that the net proceeds from the offering (before
deducting expenses) received by the Company and the Selling Holders and the
underwriting discount received by the underwriters, in each case as set forth
in the table on the cover page of the applicable prospectus, bear to the
aggregate public offering price of the Registrable Securities.  The relative fault of the Company, the
Selling Holders and the underwriters shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to
information supplied by the Company, the Selling Holders or the underwriters
and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission.  The Company, the Selling Holders, and the
underwriters agree that it would not be just and equitable if contribution
pursuant to this Section 2.4(b) were determined by pro rata or
per capita allocation or by any other method of allocation which does not take
account of the equitable considerations referred to in the immediately
preceding sentences.  In no event, however,
shall a Selling Holder be required to contribute any amount under this Section 2.4(b) in
excess of the net proceeds received by such Selling Holder from its sale of
Registrable Securities under such registration statement.  No person found guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not
found guilty of such fraudulent misrepresentation.

 

(c)          Expenses.  The amount
paid by an indemnifying party or payable to an indemnified party as a result of
the Damages shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim,
payable as the same are incurred.

 

(d)         Independent Investigation.  The
indemnification and contribution provided for in this Section 2.4
will remain in full force and effect regardless of any investigation made by or
on behalf of the indemnified parties or any officer, director, employee, agent
or controlling person of the indemnified parties.

 

Section 2.5.                                Rule 144 and Rule 144A.  The Company shall use its
best efforts to take all action as may be required as a condition to the
availability of Rule 144 or Rule 144A under the Securities Act (or
any successor or similar exemptive rules hereafter in effect).  The Company shall furnish to any Holder or
S-3 Stockholder, within fifteen (15) days of a written request, a written
statement executed by the Company as to the steps it has taken to comply with
the current public information requirement of Rule 144 or Rule 144A
or such successor rules.

 

Section 2.6.                                Most Favored Nations.  At any time that the
Company grants to other 

 

11

 

Persons either registration rights on Form S-3
(or any successor form) and/or piggyback registration rights which are, in
either case, more favorable than the rights granted in this Agreement to the
Holders or the S-3 Stockholders, the Company shall grant equivalent or more
favorable registration rights to the Holders and the S-3 Stockholders of
Registrable Securities.

 

Section 2.7.                                Mergers, Etc.  The Company shall not,
directly or indirectly, enter into any merger, consolidation or reorganization
in which the Company shall not be the surviving corporation unless the
surviving corporation shall, prior to such merger, consolidation or
reorganization, agree in writing to assume the obligations of the Company under
this Agreement, and for that purpose references hereunder to “Registrable
Securities” shall be deemed to include the shares of capital stock, if any,
that the Holders or S-3 Stockholders would be entitled to receive in exchange
for capital stock of the Company under any such merger, consolidation or reorganization;
provided, however, that, to the extent the Holders or S-3
Stockholders receive securities that are by their terms convertible into shares
of common stock of the issuer thereof, then only such shares of common stock as
are issued or issuable upon conversion of said convertible securities shall be
included within the definition of “Registrable Securities.”

 

Section 2.8.                                No Conflict of Rights.  The Company shall not, at
any time after the date hereof, grant any registration rights that conflict with
the registration rights granted hereby; provided, that the Company, subject to
compliance with Section 2.6 above, may grant any other registration
rights.

 

ARTICLE III

 

GENERAL

 

Section 3.1.                                Amendments, Waivers and
Consents.  For the purposes of this Agreement and all agreements executed pursuant
hereto, no course of dealing between or among any of the parties hereto and no
delay on the part of any party hereto in exercising any rights hereunder or
thereunder shall operate as a waiver of the rights hereof and thereof.  This Agreement may not be amended or modified
or any provision hereof waived without the joint written consent of:  (i) the Company and (ii) Stockholders
holding, together as a single class, not less than a majority of the
outstanding shares of Common Stock, calculated on a fully diluted basis, then
held by the Stockholders. 
Notwithstanding the foregoing, no amendment approved in accordance with
this Section 3.1 shall be effective if and to the extent that such
amendment (a) creates any additional affirmative obligations to be
complied with by any Stockholder that are not applicable to all Stockholders or
(b) adversely affects any Stockholder’s rights existing under this
Agreement prior to such amendment in a manner that is inconsistent with, or
disproportionate to, the effect of such amendment on the other parties hereto,
unless in each case such amendment is approved by such Stockholder.

 

Moreover, notwithstanding
the foregoing, any party may waive any
provision hereof intended for his, her or its benefit by prior written consent.

 

Notwithstanding the foregoing, any person who is the
Transferee of Registrable Securities and who executes a Joinder Agreement in
accordance with Section 3.13 shall be added to Schedule I
without the consent of any party hereto and shall be considered a Stockholder
for 

 

12

 

purposes of this Agreement.

 

Section 3.2.                                Governing Law.  This
Agreement shall be deemed to be a contract made under, and shall be construed
in accordance with, the laws of the State of Delaware, without giving effect to
conflict of laws principles thereof.

 

Section 3.3.                                Section Headings.  The
descriptive headings in this Agreement have been inserted for convenience only
and shall not be deemed to limit or otherwise affect the construction of any
provision thereof or hereof.

 

Section 3.4.                                Counterparts.  This
Agreement may be executed simultaneously in any number of counterparts, each of
which when so executed and delivered shall be taken to be an original; but such
counterparts shall together constitute but one and the same document.

 

Section 3.5.                                Notices and Demands.  Any
notice or demand which is required or provided to be given under this Agreement
shall be deemed to have been sufficiently given and received for all purposes (i) when
delivered by hand, fax, telex or other method of facsimile (but only upon
written confirmation of receipt), (ii) five (5) days after being sent
by certified or registered mail, postage and charges prepaid, return receipt
requested, or (iii) two (2) days after being sent by overnight
delivery providing receipt of delivery, to the addresses designated by the
Company and the Stockholders, respectively.

 

Section 3.6.                                Submission to Jurisdiction;
Venue.

 

(a)         Each of the parties hereto hereby irrevocably and
unconditionally submits, for itself, himself or herself and its, his or her
property, to the nonexclusive jurisdiction of any Delaware State court or any
federal court of the United States of America sitting in the State of Delaware,
and any appellate court from any thereof, in any action or proceeding arising
out of or relating to this Agreement or for recognition or enforcement of any
judgment, and each of the parties hereto hereby irrevocably and unconditionally
agrees that all claims in respect of any such action or proceeding may be heard
and determined in any such Delaware State court or, to the extent permitted by
law, in any such federal court.  Each of
the parties hereto agrees that a final judgment in any such action or
proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by law.

 

(b)         Each of the parties hereto irrevocably and
unconditionally waives, to the fullest extent that it, he or she may legally
and effectively do so, any objection that it, he or she may now or hereafter
have to the laying of venue of any suit, action or proceeding arising out of or
relating to the Agreement in any Delaware state or federal court sitting in the
State of Delaware.  Each of the parties
hereto irrevocably waives, to the fullest extent permitted by law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in any
such court.

 

(c)          The parties further agree that the mailing by
certified or registered mail, return receipt requested to both (i) the
other parties and (ii) counsel for the other parties (or such substitute
counsel as such party may have given written notice of prior to the date of
such mailing), of any process required by any such court shall constitute valid
and lawful service of process against them, without the necessity for service
by any other means provided by law.

 

13

 

Section 3.7.                                Remedies; Severability.  Notwithstanding
Section 3.6 above, it is specifically understood and agreed that
any breach of the provisions of this Agreement by any Person subject hereto
will result in irreparable injury to the other parties hereto, that the remedy
at law alone will be an inadequate remedy for such breach, and that, in
addition to any other remedies which they may have, such other parties may
enforce their respective rights by actions for specific performance (to the
extent permitted by law).  The Company
may refuse to recognize any unauthorized Transferee for purposes of the
registration rights provided in this Agreement until the relevant party or
parties have complied with all applicable provisions of this Agreement.  Whenever possible, each provision of this
Agreement shall be interpreted in such a manner as to be effective and valid
under applicable law, but if any provision of this Agreement shall be deemed
prohibited or invalid under such applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, and such
prohibition or invalidity shall not invalidate the remainder of such provision
or the other provisions of this Agreement.

 

Section 3.8.                                Waiver of Jury Trial.  NO
PARTY TO THIS AGREEMENT OR ANY ASSIGNEE, SUCCESSOR, HEIR OR PERSONAL
REPRESENTATIVE OF A PARTY SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDING,
COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON OR ARISING OUT OF
THIS AGREEMENT OR ANY OF THE OTHER AGREEMENTS OR THE DEALINGS OR THE
RELATIONSHIP BETWEEN THE PARTIES.  NO
PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION, IN WHICH A JURY TRIAL HAS
BEEN WAIVED, WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT OR HAS NOT BEEN
WAIVED.  THE PROVISIONS OF THIS SECTION HAVE
BEEN FULLY DISCUSSED BY THE PARTIES HERETO, AND THESE PROVISIONS SHALL BE
SUBJECT TO NO EXCEPTIONS.  NEITHER PARTY
HAS IN ANY WAY AGREED WITH OR REPRESENTED TO THE OTHER PARTY THAT THE
PROVISIONS OF THIS SECTION WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.

 

Section 3.9.                                Integration; Effectiveness.  This
Agreement, including the exhibits, documents and instruments referred to herein
or therein, constitutes the entire agreement, and supersedes all other prior
agreements and understandings, both written and oral, among the parties with
respect to the subject matter hereof. 
This Agreement amends, restates and replaces in its entirety the
Stockholders’ Agreement and is binding on all the parties to the Stockholders’
Agreement, and the failure of one or more parties to the Stockholders’
Agreement to sign this Agreement shall not affect such effectiveness.

 

Section 3.10.                         Successors and Assigns.  Except
as otherwise provided herein, this Agreement shall be binding upon and inure to
the benefit of and be enforceable by the successors and permitted assigns and
executors, administrators and heirs of each party hereto.  Except as contemplated hereby in connection
with a Transfer of Securities, this Agreement, and any rights or obligations
existing hereunder,may not be assigned or otherwise transferred by any party.

 

Section 3.11.                         Further Assurances.  Each
party shall cooperate and take such action as may be reasonably requested by
another party in order to carry out the provisions and purposes of this
Agreement and the transactions contemplated hereby.

 

Section 3.12.                         Term.  The
provisions of this Agreement shall terminate and be of no 

 

14

 

further force or effect upon the earlier of (i) such
time as no Stockholders hold any Registrable Securities or (ii) when the
requisite parties mutually agree to terminate the Agreement.

 

Section 3.13.                         Joinder Agreement.  The
rights of the Stockholders set forth in Article II are transferable
to each Transferee of shares of Registrable Securities. Each such Transferee
must consent in writing to be bound by the terms and conditions of this
Agreement in order to acquire the rights granted hereunder by executing a copy
of the a Joinder Agreement in the form attached hereto as Exhibit A,
which Joinder Agreement shall bind them to, and grant them the benefits of,
this Agreement as though they were original parties hereto.  For this purpose all the Stockholders and
NetSpend hereby appoint the Company as their agent and attorney to execute such
Joinder Agreement on their behalf and expressly bind themselves to the Joinder
Agreement by the Company’s execution of that Agreement without further action
on their part.

 

15

 

 

IN WITNESS WHEREOF, the undersigned have hereunto
executed this Registration Rights Agreement as of the day and year first above
written.

 

	
   

  	
  NETSPEND HOLDINGS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  

 

[First
Signature Page to Registration Rights Agreement]

 

 

	
   

  	
  OAK INVESTMENT PARTNERS X,
  LIMITED PARTNERSHIP

  
	
   

  	
   

  	
   

  
	
   

  	
  By: Oak Associates X, LLC,
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  
	
   

  	
   

  	
   

  
	
   

  	
  OAK X AFFILIATES FUND,
  L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By: Oak Associates X, LLC,
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  

 

[Second
Signature Page to Registration Rights Agreement]

 

 

	
   

  	
  SKYLIGHT HOLDINGS I, LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  

 

[Third
Signature Page to Registration Rights Agreement]

 

 

EXHIBIT A

 

Form of Joinder Agreement

 

This Joinder Agreement made this
            day
                        of
201  , by and between
                            
(the “New Stockholder”) [and the New
Stockholder’s spouse], NetSpend Holdings, Inc., a Delaware
corporation (together with any successor thereto, the “Company”),
NetSpend Corporation, a Delaware corporation and a wholly-owned subsidiary of
the Company (“NetSpend”), and the stockholders of the Company, who are
parties to that certain Registration Rights Agreement, dated as of
                  
      , 2010 (as amended, modified or
supplemented from time to time, the “Agreement”).  Capitalized terms not defined herein shall
have the meanings set forth in the Agreement.

 

WITNESSETH:

 

WHEREAS, New Stockholder is desirous of
obtaining the registration rights offered by the Agreement; and

 

WHEREAS, the Company and the Stockholders have
required in the Agreement that all Transferees of Registrable Securities must
enter into an Joinder Agreement binding the New Stockholder [and the New Stockholder’s spouse] to the
Agreement to the same extent as if they were original parties thereto.

 

NOW, THEREFORE, in consideration of the mutual
promises of the parties, the New Stockholder [and
his or her spouse] agree as follows:

 

The New Stockholder [and his or
her spouse] acknowledge that they have read the Agreement.  The New Stockholder [and his or
her spouse] shall be bound by, and shall have the benefit of, all
the terms and conditions set out in the Agreement to the same extent as if they
were “Stockholders”  as defined in
the Agreement.  This Joinder Agreement
shall be attached to and become a part of the Agreement.

 

	
   

  	
   

  	
   

  
	
  New Stockholder

  	
   

  	
  [Spouse of New Stockholder][If applicable]

  

 

 

Agreed to on behalf of the Stockholders,
NetSpend and the Company pursuant to Section  3.13 of the Agreement.

 

	
   

  	
  NETSPEND HOLDINGS, INC., a Delaware corporation

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  

 

 

SCHEDULE I

 

STOCKHOLDERS

 

I-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]